<html lang="en" class="pb-page js" data-request-id="94d69ddb368cf227-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d69ddb368cf227-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/vHpbUhvLXRPY7EdrPEpYk4lExnkEqHWtZy3HPh8dPFrI03Ty2gysNqEOqXeKcgIaoBv91xZ5cSWJ6qS_0jdlpg=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d69ddb368cf227-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.15195864705451245"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="Specialties" content="Gastroenterology">
<meta name="articleType" content="Original Article">
<meta name="articleCategory" content="Research">
<meta name="topics" content="Inflammatory Bowel Disease"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa2033617","title":"Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis","category":"Research","type":"Original Article","topics":"Inflammatory Bowel Disease","specialties":"Gastroenterology","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2021-09-30T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"Specialties\" content\u003d\"Gastroenterology\"/\u003e\n\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e\n\u003cmeta name\u003d\"topics\" content\u003d\"Inflammatory Bowel Disease\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa2033617","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":{"type":"Visual Abstract","title":"Ozanimod Therapy for Ulcerative Colitis","doi":"10.1056/NEJMdo006194","issueDate":"2021-09-30T00:00Z","age":"6Months-1990","isFree":"y","topics":"Inflammatory Bowel Disease","viewType":"Full","specialties":"Gastroenterology"}};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d69ddb368cf227-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis"><meta name="dc.Creator" content="William J. Sandborn"><meta name="dc.Creator" content="Brian G. Feagan"><meta name="dc.Creator" content="Geert D’Haens"><meta name="dc.Creator" content="Douglas C. Wolf"><meta name="dc.Creator" content="Igor Jovanovic"><meta name="dc.Creator" content="Stephen B. Hanauer"><meta name="dc.Creator" content="Subrata Ghosh"><meta name="dc.Creator" content="AnnKatrin Petersen"><meta name="dc.Creator" content="Steven Y. Hua"><meta name="dc.Creator" content="Ji Hwan Lee"><meta name="dc.Creator" content="Lorna Charles"><meta name="dc.Creator" content="Denesh Chitkara"><meta name="dc.Creator" content="Keith Usiskin"><meta name="dc.Creator" content="Jean-Frederic Colombel"><meta name="dc.Creator" content="Loren Laine"><meta name="dc.Creator" content="Silvio Danese"><meta name="dc.Description" content="Ozanimod, a selective sphingosine-1-phosphate receptor modulator, is under investigation for the treatment of inflammatory bowel disease.We conducted a phase 3, multicenter, randomized, double-blin..."><meta name="Description" content="Ozanimod, a selective sphingosine-1-phosphate receptor modulator, is under investigation for the treatment of inflammatory bowel disease.We conducted a phase 3, multicenter, randomized, double-blin..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2021-09-30"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa2033617"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202109303851408"><meta name="dc.Language" content="EN"><meta name="dc.Relation" content="YXQYoa2033617"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright © 2021 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa2033617">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa2033617">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa2033617">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis | NEJM">
        <meta property="og:title" content="Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa2033617">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/22eb968b-c730-4e0c-848f-ab35af3719fb/nejmoa2033617_f1.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/22eb968b-c730-4e0c-848f-ab35af3719fb/nejmoa2033617_f1.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="Ozanimod, a selective sphingosine-1-phosphate receptor modulator, is under investigation
for the treatment of inflammatory bowel disease. We conducted a phase 3, multicenter,
randomized, double-bli...">
        <meta name="twitter:description" content="Ozanimod, a selective sphingosine-1-phosphate receptor modulator, is under investigation
for the treatment of inflammatory bowel disease. We conducted a phase 3, multicenter,
randomized, double-bli...">
    


    
    
        <meta property="og:image:width" content="2640">
    


    
    
        <meta property="og:image:height" content="1894">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="publication_doi" content="10.1056/NEJMoa2033617">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2033617">
    
    







<meta name="pbContext" content=";issue:issue:doi\:10.1056/nejm_2021.385.issue-14;requestedJournal:journal:nejm;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:MMS NextGen Website Group;article:article:doi\:10.1056/NEJMoa2033617;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms">
        <script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2033617" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2033617" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2033617" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa2033617" class="inputDoi"><input type="hidden" value="W.J. Sandborn and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2021;385:1280-1291" class="inputCitation"><input type="hidden" value="09-29-2021" class="inputEPubDate"><input type="hidden" value="September 2021" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup modal-lg"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d69ddb368cf227-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">William J.</span> <span property="familyName">Sandborn</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Brian G.</span> <span property="familyName">Feagan</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Geert</span> <span property="familyName">D’Haens</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Douglas C.</span> <span property="familyName">Wolf</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0003-0330-8919" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0003-0330-8919</a></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Igor</span> <span property="familyName">Jovanovic</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Stephen B.</span> <span property="familyName">Hanauer</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Subrata</span> <span property="familyName">Ghosh</span>, <span property="honorificSuffix">M.D.</span></span><span data-displayed-on="all">, <span data-action="reveal" tabindex="0" role="listitem">+9</span> </span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">AnnKatrin</span> <span property="familyName">Petersen</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Steven Y.</span> <span property="familyName">Hua</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Ji Hwan</span> <span property="familyName">Lee</span>, <span property="honorificSuffix">M.S.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Lorna</span> <span property="familyName">Charles</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Denesh</span> <span property="familyName">Chitkara</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Keith</span> <span property="familyName">Usiskin</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Jean-Frederic</span> <span property="familyName">Colombel</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Loren</span> <span property="familyName">Laine</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, and <span property="author" typeof="Person" role="listitem"><span property="givenName">Silvio</span> <span property="familyName">Danese</span>, <span property="honorificSuffix">M.D.</span></span></span>, for <span property="author" typeof="Person" role="listitem">the True North Study Group<sup><a href="#fn1" role="doc-noteref">*</a></sup></span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide" tabindex="0" role="listitem">-9</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">September 29, 2021</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2021<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">385</span></span>:<span property="pageStart">1280</span>-<span property="pageEnd">1291</span></div><div class="doi">DOI: 10.1056/NEJMoa2033617</div><div class="core-enumeration"><a href="/toc/nejm/385/14"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">385</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">14</span></span></a></div><div><a href="#tab-information">Copyright © 2021</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DWilliam%2BJ.%2BSandborn%252C%2BBrian%2BG.%2BFeagan%252C%2BGeert%2BD%25E2%2580%2599Haens%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D385%26issueNum%3D14%26contentID%3D10.1056%252FNEJMoa2033617%26title%3DOzanimod%2Bas%2BInduction%2Band%2BMaintenance%2BTherapy%2Bfor%2BUlcerative%2BColitis%26publicationDate%3D09%252F30%252F2021" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa2033617" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DWilliam%2BJ.%2BSandborn%252C%2BBrian%2BG.%2BFeagan%252C%2BGeert%2BD%25E2%2580%2599Haens%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D385%26issueNum%3D14%26contentID%3D10.1056%252FNEJMoa2033617%26title%3DOzanimod%2Bas%2BInduction%2Band%2BMaintenance%2BTherapy%2Bfor%2BUlcerative%2BColitis%26publicationDate%3D09%252F30%252F2021" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/9e987e5f-6a66-478b-8956-91bb97c300f2/nejmoa2033617.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa2033617.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2033617" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2033617" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2033617.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">Ozanimod, a selective sphingosine-1-phosphate receptor modulator, is under investigation for the treatment of inflammatory bowel disease.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">We conducted a phase 3, multicenter, randomized, double-blind, placebo-controlled trial of ozanimod as induction and maintenance therapy in patients with moderately to severely active ulcerative colitis. In the 10-week induction period, patients in cohort 1 were assigned to receive oral ozanimod hydrochloride at a dose of 1 mg (equivalent to 0.92 mg of ozanimod) or placebo once daily in a double-blind manner, and patients in cohort 2 received open-label ozanimod at the same daily dose. At 10 weeks, patients with a clinical response to ozanimod in either cohort underwent randomization again to receive double-blind ozanimod or placebo for the maintenance period (through week 52). The primary end point for both periods was the percentage of patients with clinical remission, as assessed with the three-component Mayo score. Key secondary clinical, endoscopic, and histologic end points were evaluated with the use of ranked, hierarchical testing. Safety was also assessed.</div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">In the induction period, 645 patients were included in cohort 1 and 367 in cohort 2; a total of 457 patients were included in the maintenance period. The incidence of clinical remission was significantly higher among patients who received ozanimod than among those who received placebo during both induction (18.4% vs. 6.0%, P&lt;0.001) and maintenance (37.0% vs. 18.5% [among patients with a response at week 10], P&lt;0.001). <a id="exam-tint-two-b"></a><span id="tint1" class="named-content" data-type="exam-tint" data-answer-ids="two-b">The incidence of clinical response was also significantly higher with ozanimod than with placebo during induction (47.8% vs. 25.9%, P&lt;0.001) and maintenance (60.0% vs. 41.0%, P&lt;0.001).</span> All other key secondary end points were significantly improved with ozanimod as compared with placebo in both periods. The incidence of infection (of any severity) with ozanimod was similar to that with placebo during induction and higher than that with placebo during maintenance. Serious infection occurred in less than 2% of the patients in each group during the 52-week trial. Elevated liver aminotransferase levels were more common with ozanimod.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">Ozanimod was more effective than placebo as induction and maintenance therapy in patients with moderately to severely active ulcerative colitis. (Funded by Bristol Myers Squibb; True North ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT02435992" target="_blank">NCT02435992</a>.)</div></section></section><div class="core-digital-object visual-abstract">
<div class="ng-page_separator pt-24"></div>
<div class="ng-do-media">
    <button data-toggle="modal" data-target="#doPopup" class="ng-do-media_btn" modal-size="lg"></button>
    <div data-ajaxurl="/do/10.1056/NEJMdo006194/full/?ajaxRequest=true" class="ng-do-media_item">
        <div class="ng-do-media_item-left">
            <a href="#" class="ng-do-media_item-img-link" data-interactiontype="multimedia_click" data-multimedia-type="Visual Abstract" data-multimedia-contentid="10.1056/NEJMdo006194" data-multimedia-filename="NEJMdo006194_600x400.jpg">
                <img src="/cms/asset/8dbc7060-6311-49a2-becf-c04aeb06f465/media/NEJMdo006194_300x200.jpg" class="ng-do-media_item-img">
                <span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#tooltip-visual"></use></svg></span>
            </a>
        </div>
        <div class="ng-do-media_item-right">
            <div class="ng-do-media_item-type">
                <a href="/browse/nejm-media-type/visual-abstract" class="ng-do-media_item-type-link">Visual Abstract</a>
            </div>
            <h6 class="ng-do-media_item-title">
                <a href="#" class="ng-do-media_item-title-link" data-interactiontype="multimedia_click" data-multimedia-type="Visual Abstract" data-multimedia-contentid="10.1056/NEJMdo006194" data-multimedia-filename="NEJMdo006194_600x400.jpg">Ozanimod Therapy for Ulcerative Colitis</a>
            </h6>
        </div>
    </div>
</div>

</div></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">Ulcerative colitis is a chronic disease that is characterized by a dysregulated immune response and chronic inflammation in the colonic mucosa.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1" id="body-ref-r1" href-manipulated="true" aria-label="Reference 1">1</a></sup> Conventional therapies such as aminosalicylates are modestly effective in patients with moderate, but not severe, disease.<sup><a href="#core-r2" role="doc-biblioref" data-xml-rid="r2" id="body-ref-r2-1" href-manipulated="true" aria-label="Reference 2">2</a></sup> Glucocorticoids have been associated with adverse events and long-term adverse health consequences and are not recommended as maintenance therapy.<sup><a href="#core-r2" role="doc-biblioref" data-xml-rid="r2 r3 r4" id="body-ref-r4" href-manipulated="true">2-4</a></sup> Newer agents, including biologic drugs and Janus kinase inhibitors, are not effective in all patients or can lose efficacy with long-term use, and they have been associated with infections, infusion reactions, and cancers.<sup><a href="#core-r5" role="doc-biblioref" data-xml-rid="r5 r6" id="body-ref-r6" href-manipulated="true">5,6</a></sup> Thus, the need remains for new oral treatments for ulcerative colitis that are safe and glucocorticoid-sparing and that have durable efficacy.<sup><a href="#core-r2" role="doc-biblioref" data-xml-rid="r2" id="body-ref-r2-3" href-manipulated="true" aria-label="Reference 2">2</a></sup></div><div role="paragraph"><a id="exam-tint-one-a"></a><a id="exam-tint-one-b"></a><a id="exam-tint-one-c"></a><a id="exam-tint-one-d"></a><span id="tint2" class="named-content" data-type="exam-tint" data-answer-ids="one-a one-b one-c one-d">Ozanimod is a sphingosine-1-phosphate (S1P) receptor modulator that binds with high affinity to S1P subtypes 1 and 5 (S1P1 and S1P5), leading to internalization of S1P1 receptors in lymphocytes and the prevention of lymphocyte mobilization to inflammatory sites.<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7 r8 r9" id="body-ref-r9" href-manipulated="true">7-9</a></sup> In a phase 2 trial, treatment with ozanimod showed significant improvements over placebo with regard to endoscopic, histologic, and clinical end points in patients with moderate-to-severe ulcerative colitis.</span><sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10" id="body-ref-r10-1" href-manipulated="true" aria-label="Reference 10">10</a></sup> A separate phase 2 trial showed benefits with ozanimod therapy in patients with Crohn’s disease.<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11" id="body-ref-r11-1" href-manipulated="true" aria-label="Reference 11">11</a></sup> To date, the safety profile of ozanimod, as characterized on the basis of studies involving more than 4000 patients with ulcerative colitis, Crohn’s disease, or relapsing multiple sclerosis and healthy volunteers, is consistent across populations. Several adverse events of special interest that are known to be associated with S1P receptor modulation (e.g., bradycardia, serious or opportunistic infections, macular edema, and elevated liver-enzyme levels) were monitored in the clinical trials.<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10 r11 r12 r13 r14 r15" id="body-ref-r15-1" href-manipulated="true">10-15</a></sup> We report here the results of True North, a 52-week, phase 3 trial to evaluate ozanimod as induction and maintenance therapy in patients with moderately to severely active ulcerative colitis.</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Trial Oversight</h3><div role="paragraph">We conducted this randomized, double-blind, placebo-controlled trial at 285 sites in 30 countries. The <a href="#ap1">protocol</a>, available with the full text of this article at NEJM.org, was approved by the institutional review board at each center. All the patients provided written informed consent.</div><div role="paragraph">The members of the steering committee designed the trial in collaboration with the sponsor (Bristol Myers Squibb). Data were compiled by the sponsor; Pharmaceutical Product Development provided assistance with statistical programming. All the authors had full access to the data. The first author wrote the first draft of the manuscript. Editorial assistance was funded by Bristol Myers Squibb. The eighth and ninth authors, both employees of the sponsor, vouch for the completeness and accuracy of the data, and the eighth author vouches for the adherence of the trial to the protocol.</div></section><section id="sec-1-2"><h3>Patients</h3><div role="paragraph">Eligible patients were 18 to 75 years of age and had moderately to severely active ulcerative colitis, defined as a total Mayo score of 6 to 12, with an endoscopy subscore of 2 or higher, a rectal-bleeding subscore of 1 or higher, and a stool-frequency subscore of 1 or higher. Each subscore category is rated on a scale from 0 to 3, which was summed to give a total Mayo score between 0 and 12; higher scores indicate greater activity.<sup><a href="#core-r16" role="doc-biblioref" data-xml-rid="r16" id="body-ref-r16" href-manipulated="true" aria-label="Reference 16">16</a></sup></div><div role="paragraph">Patients were required to have received stable doses of oral aminosalicylates or glucocorticoids (prednisone at a dose of ≤20 mg per day or budesonide) or both for at least 2 weeks before screening endoscopy and to continue receiving the same dose for the duration of the induction period; the glucocorticoid dose had to be tapered once the patient entered the maintenance period. A documented presence of varicella–zoster virus IgG antibody or complete varicella–zoster vaccination at least 30 days before randomization was also required. Patients were excluded from the trial if they had not had a response to induction therapy with at least two biologic agents approved for the treatment of ulcerative colitis, had a clinically relevant cardiac condition, or had a history of uveitis or macular edema. The full enrollment criteria are provided in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org.</div></section><section id="sec-1-3"><h3>Trial Design</h3><div role="paragraph">After a screening period of up to 5 weeks, patients entered a 10-week induction period. First, in cohort 1, patients were randomly assigned in a 2:1 ratio to receive ozanimod hydrochloride at a dose of 1 mg per day (equivalent to 0.92 mg of ozanimod; referred to hereafter as ozanimod) or matched placebo once daily in a double-blind manner. Randomization was conducted by means of a centralized interactive voice- and Web-based activated response system (IxRS). Once the percentage of patients with previous exposure to a tumor necrosis factor (TNF) antagonist reached 30% in cohort 1, the IxRS assigned patients with TNF antagonist exposure to cohort 2, in which patients received open-label ozanimod at the same daily dose. Patients without previous TNF antagonist exposure continued to undergo randomization in cohort 1 until enrollment was closed, at which time such patients were assigned to cohort 2. The percentage of patients with TNF antagonist exposure was capped at 50% in cohort 2. Cohort 2 was included to increase the number of patients with a response who would be available for randomization in the maintenance phase of the trial. A 7-day period of dose escalation with ozanimod — starting at 0.25 mg on days 1 to 4 and progressing to 0.5 mg on days 5 to 7 and to 1 mg thereafter — was incorporated to minimize the risk of bradycardia that has been reported with some S1P modulators within the first few hours after administration.<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17 r18" id="body-ref-r18" href-manipulated="true">17,18</a></sup></div><div role="paragraph">Ozanimod-treated patients who had a clinical response (defined as a reduction in the total Mayo score of ≥3 points and ≥30% from baseline or in the three-component Mayo score of ≥2 points and ≥35% from baseline, as well as a reduction in the rectal-bleeding subscore of ≥1 point or an absolute rectal-bleeding subscore of ≤1 point) at week 10 were eligible to undergo randomization again, in a 1:1 ratio, to receive either ozanimod or placebo in a double-blind manner through week 52 (maintenance period). Patients who had a clinical response while they were receiving placebo at the end of the induction period continued to receive double-blind placebo during the maintenance period. Patients without a clinical response during the induction period could enter an open-label extension trial at week 10, whereas patients who were included in the maintenance period could enter the extension trial at week 52 or after disease relapse (defined as a partial Mayo score [i.e., the rectal-bleeding subscore, stool-frequency subscore, and physician’s global assessment subscore] of ≥4 points or a ≥2-point increase from week 10, as well as an endoscopy subscore of ≥2 points) (Fig. S1 in the <a href="#ap2">Supplementary Appendix</a>).</div></section><section id="sec-1-4"><h3>Assessments and End Points</h3><div role="paragraph">Endoscopic and histologic end points were determined by one central reader who used blinded videos of endoscopic procedures and preserved biopsy samples, respectively. Rectal bleeding and stool frequency were reported by patients in an electronic diary. The primary efficacy end point was the percentage of patients with clinical remission at week 10 (for the induction period) and at week 52 (for the maintenance period), assessed on the basis of the three-component Mayo score. Clinical remission was defined as follows: a rectal-bleeding subscore of 0; a stool-frequency subscore of 1 or less, with a decrease of at least 1 point from baseline; and an endoscopy subscore of 1 or less (all on scales from 0 [none] to 3 [most severe]).<sup><a href="#core-r19" role="doc-biblioref" data-xml-rid="r19" id="body-ref-r19" href-manipulated="true" aria-label="Reference 19">19</a></sup></div><div role="paragraph">The key secondary efficacy end points were assessed in a closed, prespecified hierarchical testing procedure. The ranked secondary end points for the induction period (at week 10) were the percentages of patients with a clinical response (based on the three-component Mayo score; see above), endoscopic improvement (defined as a mucosal endoscopy subscore of ≤1 without friability), and mucosal healing (endoscopic improvement plus histologic remission, defined as a mucosal endoscopy score of ≤1 and a Geboes score of &lt;2.0 [on a scale from 0 to 5.4, with higher scores indicating more severe inflammation<sup><a href="#core-r20" role="doc-biblioref" data-xml-rid="r20" id="body-ref-r20" href-manipulated="true" aria-label="Reference 20">20</a></sup>]). The ranked secondary end points for the maintenance period (at week 52) were the percentages of patients with a clinical response, endoscopic improvement, maintenance of clinical remission (remission at week 52 in the subgroup of patients with remission at week 10), glucocorticoid-free remission (remission with no glucocorticoid use for ≥12 weeks), mucosal healing, and durable clinical remission (remission at weeks 10 and 52, assessed in all patients in the maintenance period).</div><div role="paragraph">Other prespecified end points included histologic remission and clinical remission in subgroups defined according to demographic and disease-based characteristics. Tables S1 and S2 list the prespecified efficacy end points. The time to disease relapse was examined as an exploratory end point. Reductions in rectal bleeding and stool frequency were assessed in post hoc analyses, and changes in biomarkers such as fecal calprotectin and C-reactive protein levels were examined.</div><div role="paragraph">Safety assessments were based on adverse events that occurred during the trial. <a id="exam-tint-three-a"></a><a id="exam-tint-three-b"></a><a id="exam-tint-three-c"></a><a id="exam-tint-three-d"></a><span id="tint3" class="named-content" data-type="exam-tint" data-answer-ids="three-a three-b three-c three-d">Bradycardia, cardiac conduction abnormalities (second-degree and higher atrioventricular block), macular edema, cancer, serious or opportunistic infection, pulmonary effects, and hepatic effects were examined as adverse events of special interest on the basis of previous associations with S1P receptor modulation.</span><sup><a href="#core-r21" role="doc-biblioref" data-xml-rid="r21 r22" id="body-ref-r22" href-manipulated="true">21,22</a></sup> Clinical laboratory measurements were performed at a central laboratory. Assessment of vital signs, pulmonary-function testing, ophthalmologic examination (including optical coherence tomography), and electrocardiography (before and 6 hours after the first dose) were also performed. Leukocyte counts, including lymphocyte subsets, were not provided to investigators. Additional information about the methods is provided in the <a href="#ap2">Supplementary Appendix</a>.</div></section><section id="sec-1-5"><h3>Statistical Analysis</h3><div role="paragraph">The demographic and clinical characteristics of the patients at baseline were summarized descriptively. Efficacy analyses were based on all patients who underwent randomization and received at least one dose of ozanimod or placebo (modified intention-to-treat population). Statistical comparisons of efficacy end points for the induction period were performed in cohort 1 only. Clinical remission was analyzed with the use of a two-sided Cochran–Mantel–Haenszel test at the 5% significance level, with accounting for stratification according to glucocorticoid use at screening and previous TNF antagonist use for the induction period (week 10) and according to clinical remission status at week 10 and glucocorticoid use at week 10 for the maintenance period (week 52).</div><div role="paragraph">The key secondary end points were evaluated with the use of a two-sided Cochran–Mantel–Haenszel test following a closed, prespecified hierarchical testing procedure to control the overall type I error rate for multiple end points (with an alpha of 0.05 allocated for each of the induction and maintenance periods of the trial). If the primary end point in each period was significant, key secondary end points were analyzed in sequence until a 5% significance level was not reached, after which all the subsequent ranked secondary end points were to be considered exploratory. For end points that were not included in the hierarchies, point estimates and 95% confidence intervals are reported, without P values. The confidence intervals were not adjusted for multiple comparisons and should not be used to infer definitive treatment effects. Patients with missing efficacy data were considered as not having had a response. A missing-at-random assumption was not considered to be appropriate for the data. Sensitivity analyses were conducted for the primary and first key secondary end points with the use of an observed-cases analysis (assumption of data missing completely at random) and with the use of multiple imputation (assumption of data missing at random).<sup><a href="#core-r23" role="doc-biblioref" data-xml-rid="r23" id="body-ref-r23" href-manipulated="true" aria-label="Reference 23">23</a></sup></div><div role="paragraph">We calculated that a sample of 600 patients (randomly assigned in a 2:1 ratio in cohort 1 in the induction period) would provide the trial with at least 90% power to detect a between-group difference of 10 percentage points in the incidence of clinical remission during the induction period. Cohort 2 (with a planned sample of 300 patients) was used to ensure that the trial would have an enrollment of 400 patients in the maintenance period, with the trial having 90% power for the primary end point. Additional details regarding the statistical analysis are provided in the <a href="#ap2">Supplementary Appendix</a>. Safety results were summarized descriptively for all patients who received at least one dose of ozanimod or placebo (safety population).</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Randomization and Baseline Characteristics of the Patients</h3><div role="paragraph">The trial was conducted from May 2015 through June 2020. Of the 1831 patients who underwent screening, 1012 were enrolled in the trial. A total of 645 patients entered cohort 1 and were randomly assigned to receive either ozanimod (429 patients) or placebo (216 patients) in a double-blind manner; 367 patients received open-label ozanimod in cohort 2 (<a href="#f1">Figure 1</a>). In cohort 1, a total of 401 patients (93.5%) who had been assigned to receive ozanimod and 192 (88.9%) who had been assigned to receive placebo completed the induction period. The most common reasons for discontinuation in the induction period were adverse events (in 11 patients [2.6%] in the ozanimod group) and lack of efficacy (in 10 [4.6%] in the placebo group).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2033617_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2033617_f1.jpg"><img src="/cms/10.1056/NEJMoa2033617/asset/22eb968b-c730-4e0c-848f-ab35af3719fb/assets/images/large/nejmoa2033617_f1.jpg" height="1894" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Randomization and Follow-up of the Patients in the Induction and Maintenance Periods.</div><div class="notes"><div role="doc-footnote">The most common reasons for ineligibility were disease criteria not met (in 18.1% of the patients who underwent screening), a lack of documentation of varicella–zoster virus IgG antibodies or vaccination (in 5.7%), inability to provide informed consent or to comply with protocol assessments (in 4.6%), and presence of <i>Clostridium difficile</i> or other stool pathogens (in 3.7%). In cohort 1, patients were randomly assigned to receive ozanimod or placebo; once the percentage of patients with previous exposure to a tumor necrosis factor (TNF) antagonist reached 30%, subsequent patients with TNF antagonist exposure were assigned to cohort 2, in which they received open-label ozanimod. Clinical response was defined as a reduction of at least 3 points and of at least 30% from baseline in the total Mayo score or a reduction of at least 2 points and of at least 35% from baseline in the three-component Mayo score, plus a reduction of at least 1 point in the rectal-bleeding score or an absolute rectal-bleeding score of no more than 1 point. The total Mayo score is defined as the sum of the rectal-bleeding subscore, the stool-frequency subscore, the physician’s global assessment subscore, and the endoscopy subscore; overall scores range from 0 to 12 (with each subscore on a scale from 0 to 3), with higher scores indicating greater activity. The three-component Mayo score is defined as the sum of the rectal-bleeding subscore, the stool-frequency subscore, and the endoscopy subscore; overall scores range from 0 to 9 (with each subscore ranging from 0 to 3), with higher scores indicating greater activity.</div></div></figcaption></figure></div><div role="paragraph">At the completion of the induction period, 233 patients (54.3%) in cohort 1 and 224 (61.0%) in cohort 2 had a clinical response to ozanimod therapy and underwent randomization again to receive either ozanimod (230 patients) or placebo (227 patients) in the maintenance period. A total of 184 patients (80.0%) who had been assigned to receive ozanimod and 124 (54.6%) who had been assigned to receive placebo completed the maintenance period. The most common reason for discontinuation in the maintenance period was disease relapse (in 31 patients [13.5%] in the ozanimod group and in 77 [33.9%] in the placebo group). The demographic and clinical characteristics of the patients were similar in the two groups (<a href="#t1">Table 1</a>).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2033617_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2033617_t1.jpg"><img src="/cms/10.1056/NEJMoa2033617/asset/c6154390-a71f-490a-b43b-58a97ed224c5/assets/images/large/nejmoa2033617_t1.jpg" height="2814" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders" colspan="2"><span>Cohort 1</span></th><th class="txxr-borders">Cohort 2</th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Placebo<br>(N=216)</th><th class="xxxx-borders">Ozanimod<br>(N=429)</th><th class="xxxr-borders">Ozanimod<br>(N=367)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Male sex — no. (%)</td><td class="xxxx-borders shading">143 (66.2)</td><td class="xxxx-borders shading">245 (57.1)</td><td class="xxxr-borders shading">214 (58.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Age — yr</td><td class="xxxx-borders">41.9±13.6</td><td class="xxxx-borders">41.4±13.5</td><td class="xxxr-borders">42.1±13.7</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Body-mass index<a href="#t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">25.1±4.5</td><td class="xxxx-borders shading">25.4±5.5</td><td class="xxxr-borders shading">25.9±5.8</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Time since diagnosis of ulcerative colitis — yr</td><td class="xxxx-borders">6.8±7.0</td><td class="xxxx-borders">6.9±6.6</td><td class="xxxr-borders">7.9±7.4</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Extent of disease — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Left side of colon</td><td class="xxxx-borders">134 (62.0)</td><td class="xxxx-borders">268 (62.5)</td><td class="xxxr-borders">237 (64.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Extensive</td><td class="xxxx-borders shading">82 (38.0)</td><td class="xxxx-borders shading">161 (37.5)</td><td class="xxxr-borders shading">130 (35.4)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Mayo score</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Total score<a href="#t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">8.9±1.4</td><td class="xxxx-borders shading">8.9±1.5</td><td class="xxxr-borders shading">9.1±1.5</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Three-component score<a href="#t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">6.6±1.2</td><td class="xxxx-borders">6.6±1.2</td><td class="xxxr-borders">6.8±1.3</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Fecal calprotectin — μg/g</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Median</td><td class="xxxx-borders">1350</td><td class="xxxx-borders">1080</td><td class="xxxr-borders">1260</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Interquartile range</td><td class="xxxx-borders shading">345–3075</td><td class="xxxx-borders shading">399–2532</td><td class="xxxr-borders shading">421–2881</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">C-reactive protein — mg/liter</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Median</td><td class="xxxx-borders shading">5.0</td><td class="xxxx-borders shading">4.0</td><td class="xxxr-borders shading">5.0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Interquartile range</td><td class="xxxx-borders">2.0–12.0</td><td class="xxxx-borders">1.0–9.0</td><td class="xxxr-borders">2.0–11.0</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Concomitant medication use — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Systemic glucocorticoid</td><td class="xxxx-borders">70 (32.4)</td><td class="xxxx-borders">119 (27.7)</td><td class="xxxr-borders">124 (33.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Budesonide</td><td class="xxxx-borders shading">13 (6.0)</td><td class="xxxx-borders shading">19 (4.4)</td><td class="xxxr-borders shading">23 (6.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Oral aminosalicylate</td><td class="xxxx-borders">182 (84.3)</td><td class="xxxx-borders">374 (87.2)</td><td class="xxxr-borders">315 (85.8)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Previous medication use</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Glucocorticoid — no. (%)</td><td class="xxxx-borders">162 (75.0)</td><td class="xxxx-borders">322 (75.1)</td><td class="xxxr-borders">286 (77.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Immunomodulator — no. (%)</td><td class="xxxx-borders shading">93 (43.1)</td><td class="xxxx-borders shading">174 (40.6)</td><td class="xxxr-borders shading">166 (45.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Oral aminosalicylate — no. (%)</td><td class="xxxx-borders">210 (97.2)</td><td class="xxxx-borders">418 (97.4)</td><td class="xxxr-borders">362 (98.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Vedolizumab — no. (%)</td><td class="xxxx-borders shading">38 (17.6)</td><td class="xxxx-borders shading">71 (16.6)</td><td class="xxxr-borders shading">93 (25.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Tofacitinib — no. (%)</td><td class="xxxx-borders">4 (1.9)</td><td class="xxxx-borders">3 (0.7)</td><td class="xxxr-borders">13 (3.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">TNF inhibitor — no. (%)<a href="#t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">65 (30.1)</td><td class="xxxx-borders shading">130 (30.3)</td><td class="xxxr-borders shading">159 (43.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Had a primary nonresponse — no./total no. (%)</td><td class="xxxx-borders">21/65 (32)</td><td class="xxxx-borders">49/130 (38)</td><td class="xxxr-borders">60/159 (38)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Had a secondary nonresponse — no./total no. (%)</td><td class="xxxx-borders shading">42/65 (65)</td><td class="xxxx-borders shading">84/130 (65)</td><td class="xxxr-borders shading">109/159 (69)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging23" data-xml-align="left">Had received vedolizumab previously — no./total no. (%)</td><td class="xbxx-borders">29/65 (45)</td><td class="xbxx-borders">62/130 (48)</td><td class="xbxr-borders">88/159 (55)</td></tr></tbody></table></div><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients at Baseline in the Induction Period (Modified Intention-to-Treat Population).<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">Plus–minus values are means ±SD. The modified intention-to-treat population included all the patients who underwent randomization and received at least one dose of ozanimod or placebo. In cohort 1, patients were randomly assigned to receive ozanimod or placebo; once the percentage of patients with previous exposure to a tumor necrosis factor (TNF) antagonist reached 30%, subsequent patients with TNF antagonist exposure were assigned to cohort 2, in which they received open-label ozanimod.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t1fn2" role="paragraph">The body-mass index is the weight in kilograms divided by the square of the height in meters.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t1fn3" role="paragraph">The total Mayo score is defined as the sum of the rectal-bleeding subscore, the stool-frequency subscore, the physician’s global assessment subscore, and the endoscopy subscore. Overall scores range from 0 to 12 (with each subscore on a scale from 0 to 3), with higher scores indicating greater activity. Scores were assessed by a central reader.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t1fn4" role="paragraph">The three-component Mayo score is defined as the sum of the rectal-bleeding subscore, the stool-frequency subscore, and the endoscopy subscore. Overall scores range from 0 to 9 (with each subscore on a scale from 0 to 3), with higher scores indicating greater activity. Scores were assessed by a central reader.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t1fn5" role="paragraph">Percentages in this category are based on the subgroup of patients who were treated with a TNF inhibitor. Data were from case-report forms. Patients may be classified under more than one response category if they had received more than one previous anti-TNF therapy and had a different response to each therapy. Primary nonresponse was defined as signs and symptoms of persistently active disease despite an adequate trial of induction treatment with an anti-TNF agent. Secondary nonresponse was defined as the recurrence of symptoms during maintenance therapy after a previous clinical benefit.</div></div></div></figcaption></figure></div></section><section id="sec-2-2"><h3>Efficacy Outcomes in the Induction Period</h3><div role="paragraph"><a id="exam-tint-two-a"></a><span id="tint4" class="named-content" data-type="exam-tint" data-answer-ids="two-a">At week 10, the percentage of patients with clinical remission was significantly higher in the ozanimod group than in the placebo group (18.4% vs. 6.0%, P&lt;0.001) (<a href="#f2">Figure 2A</a>).</span> Significant improvements with ozanimod as compared with placebo were also observed with regard to the three ranked key secondary end points of clinical response, endoscopic improvement, and mucosal healing (P&lt;0.001 for all comparisons). The percentage of patients with histologic remission (an additional secondary end point) was 10.8 percentage points (95% confidence interval, 5.8 to 15.8) higher with ozanimod than with placebo (Fig. S2). Prespecified subgroup analyses for the primary end point of clinical remission during the induction period are shown in Figure S3. Efficacy results among the patients in cohort 2 were similar to the results among the patients treated with ozanimod in cohort 1 (Table S3).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 2</div><nav><a href="#f2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2033617_f2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f2" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2033617_f2.jpg"><img src="/cms/10.1056/NEJMoa2033617/asset/2ac4695c-d58a-4392-87c7-951673283104/assets/images/large/nejmoa2033617_f2.jpg" height="1939" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Efficacy Results for Ozanimod as Induction and Maintenance Therapy, as Compared with Placebo (Modified Intention-to-Treat Population).</div><div class="notes"><div role="doc-footnote">Panel A shows the primary end point (shaded area) and key secondary end points from the induction period (cohort 1) at week 10, and Panel B the primary end point (shaded area) and key secondary end points from the maintenance period at week 52. Percentages of patients with each end point (as well as the numbers and total numbers of patients) are shown, and between-group differences are shown in percentage points with 95% confidence intervals (CI). End points are shown in the order from the hierarchical testing procedure. The modified intention-to-treat population included all patients who underwent randomization and received at least one dose of ozanimod or placebo. Analysis in the induction period was based on the two-sided Cochran–Mantel–Haenszel test and stratified according to glucocorticoid use at screening and previous use of a TNF antagonist. Analysis in the maintenance period was based on the two-sided Cochran–Mantel–Haenszel test and stratified according to clinical remission status at week 10 of the induction period and glucocorticoid use at week 10 of the induction period. Missing data were handled with the use of a “nonresponse” imputation.</div><div role="doc-footnote">Clinical remission was defined as a rectal-bleeding subscore of 0, a stool-frequency subscore of 1 or less (plus a ≥1-point reduction from baseline), and a mucosal endoscopy subscore of 1 or less, without friability. Clinical response was defined as a reduction in the three-component Mayo score of at least 2 points and at least 35% from baseline, as well as a reduction in the rectal-bleeding subscore of at least 1 point or an absolute rectal-bleeding subscore of 1 or less. Endoscopic improvement was defined as a mucosal endoscopy subscore of 1 or less, without friability. Mucosal healing was defined as endoscopic improvement plus histologic remission (i.e., a Geboes score of &lt;2.0 [on a scale from 0 to 5.4, with higher scores indicating more severe inflammation] and an absence of neutrophils in the epithelial crypts or lamina propria and no increase in eosinophils, no crypt destruction, and no erosions, ulcerations, or granulation tissue). Maintenance of remission was defined as clinical remission at 52 weeks in the subgroup of patients with remission at week 10. Glucocorticoid-free remission was defined as clinical remission at 52 weeks without receipt of glucocorticoids for at least 12 weeks. Durable remission was defined as remission at both weeks 10 and 52.</div></div></figcaption></figure></div></section><section id="sec-2-3"><h3>Efficacy Outcomes in the Maintenance Period</h3><div role="paragraph"><a id="exam-tint-two-c"></a><span id="tint5" class="named-content" data-type="exam-tint" data-answer-ids="two-a two-c">Among the 457 patients who had a response to ozanimod during the induction period and underwent subsequent randomization in the maintenance period, 37.0% in the ozanimod group and 18.5% in the placebo group had clinical remission at week 52 (P&lt;0.001) (<a href="#f2">Figure 2B</a>). All the ranked key secondary end points were also significantly improved with ozanimod therapy, as compared with placebo, at week 52; improvement in the incidence of histologic remission (an additional secondary end point) also occurred with ozanimod therapy (<a href="#f2">Figure 2B</a> and Tables S4 and S6).</span> The time to disease relapse (an exploratory end point) during the maintenance period is shown in Figure S4.</div><div role="paragraph">Prespecified subgroup analyses for the primary end point of clinical remission during the maintenance period are shown in Figure S5. <a id="exam-tint-two-d"></a><span id="tint6" class="named-content" data-type="exam-tint" data-answer-ids="two-d">Treatment-effect sizes in patients with TNF antagonist exposure were similar to those in patients without such exposure</span>. Results of sensitivity analyses of the primary end point (during both the induction and maintenance periods) were consistent with those of the primary analysis (Table S5).</div></section><section id="sec-2-4"><h3>Additional End Points</h3><div role="paragraph">A post hoc analysis showed decreases in the rectal-bleeding and stool-frequency subscores by week 2 (i.e., 1 week after the completion of dose adjustment during the induction period) in patients receiving ozanimod (Figs. S6 and S7). Greater reductions from baseline in fecal calprotectin levels were also observed with ozanimod than with placebo in both the induction and maintenance periods (Table S7).</div></section><section id="sec-2-5"><h3>Safety</h3><div role="paragraph"><span id="tint7" class="named-content" data-type="exam-tint" data-answer-ids="three-d">The overall incidence of adverse events was higher in the ozanimod group than in the placebo group during the maintenance period and was similar among the groups during the induction period.</span> The overall incidence of nonserious infection with ozanimod therapy was similar to that with placebo during the induction period but was higher than that with placebo during the maintenance period (<a href="#t2">Table 2</a>). The frequency of serious infections was less than 2% in each group. One death (in cohort 2) occurred in a patient with a history of ischemic cardiomyopathy and prolonged tobacco use, in whom influenza and acute respiratory distress syndrome developed.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2033617_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2033617_t2.jpg"><img src="/cms/10.1056/NEJMoa2033617/asset/36dd9d86-6808-4b8e-b523-493e7b90fc12/assets/images/large/nejmoa2033617_t2.jpg" height="2778" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Variable</th><th class="txxx-borders" colspan="3"><span>Induction Period</span></th><th class="txxr-borders" colspan="2"><span>Maintenance Period<a href="#t2fn2" role="doc-noteref">†</a></span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders" colspan="2"><span>Cohort 1</span></th><th class="xxxx-borders">Cohort 2</th><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr class="head2" data-type="row head2" data-xml-valign="top"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Placebo<br>(N=216)</th><th class="xxxx-borders">Ozanimod<br>(N=429)</th><th class="xxxx-borders">Ozanimod<br>(N=367)</th><th class="xxxx-borders">Placebo<br>(N=227)</th><th class="xxxr-borders">Ozanimod<br>(N=230)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Adverse event — no. (%)</td><td class="xxxx-borders shading">82 (38.0)</td><td class="xxxx-borders shading">172 (40.1)</td><td class="xxxx-borders shading">146 (39.8)</td><td class="xxxx-borders shading">83 (36.6)</td><td class="xxxr-borders shading">113 (49.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Serious adverse event — no. (%)</td><td class="xxxx-borders">7 (3.2)</td><td class="xxxx-borders">17 (4.0)</td><td class="xxxx-borders">23 (6.3)</td><td class="xxxx-borders">18 (7.9)</td><td class="xxxr-borders">12 (5.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Serious adverse event related to ozanimod or placebo — no. (%)</td><td class="xxxx-borders shading">2 (0.9)</td><td class="xxxx-borders shading">1 (0.2)</td><td class="xxxx-borders shading">3 (0.8)</td><td class="xxxx-borders shading">1 (0.4)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Adverse event leading to discontinuation of the regimen — no. (%)</td><td class="xxxx-borders">7 (3.2)</td><td class="xxxx-borders">14 (3.3)</td><td class="xxxx-borders">14 (3.8)</td><td class="xxxx-borders">6 (2.6)</td><td class="xxxr-borders">3 (1.3)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Most frequent adverse events — no. (%)<a href="#t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Anemia</td><td class="xxxx-borders">12 (5.6)</td><td class="xxxx-borders">18 (4.2)</td><td class="xxxx-borders">16 (4.4)</td><td class="xxxx-borders">4 (1.8)</td><td class="xxxr-borders">3 (1.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Nasopharyngitis</td><td class="xxxx-borders shading">3 (1.4)</td><td class="xxxx-borders shading">15 (3.5)</td><td class="xxxx-borders shading">10 (2.7)</td><td class="xxxx-borders shading">4 (1.8)</td><td class="xxxr-borders shading">7 (3.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Headache</td><td class="xxxx-borders">4 (1.9)</td><td class="xxxx-borders">14 (3.3)</td><td class="xxxx-borders">10 (2.7)</td><td class="xxxx-borders">1 (0.4)</td><td class="xxxr-borders">8 (3.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Alanine aminotransferase increased<a href="#t2fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">11 (2.6)</td><td class="xxxx-borders shading">6 (1.6)</td><td class="xxxx-borders shading">1 (0.4)</td><td class="xxxr-borders shading">11 (4.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Arthralgia</td><td class="xxxx-borders">3 (1.4)</td><td class="xxxx-borders">10 (2.3)</td><td class="xxxx-borders">5 (1.4)</td><td class="xxxx-borders">6 (2.6)</td><td class="xxxr-borders">7 (3.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">γ-Glutamyltransferase increased<a href="#t2fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">5 (1.2)</td><td class="xxxx-borders shading">6 (1.6)</td><td class="xxxx-borders shading">1 (0.4)</td><td class="xxxr-borders shading">7 (3.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Infection — no. (%)</td><td class="xxxx-borders">25 (11.6)</td><td class="xxxx-borders">46 (10.7)</td><td class="xxxx-borders">46 (12.5)</td><td class="xxxx-borders">27 (11.9)</td><td class="xxxr-borders">53 (23.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Serious infection</td><td class="xxxx-borders shading">1 (0.5)</td><td class="xxxx-borders shading">4 (0.9)</td><td class="xxxx-borders shading">6 (1.6)</td><td class="xxxx-borders shading">4 (1.8)</td><td class="xxxr-borders shading">2 (0.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Nasopharyngitis</td><td class="xxxx-borders">3 (1.4)</td><td class="xxxx-borders">15 (3.5)</td><td class="xxxx-borders">10 (2.7)</td><td class="xxxx-borders">4 (1.8)</td><td class="xxxr-borders">7 (3.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Upper respiratory tract infection</td><td class="xxxx-borders shading">1 (0.5)</td><td class="xxxx-borders shading">5 (1.2)</td><td class="xxxx-borders shading">8 (2.2)</td><td class="xxxx-borders shading">4 (1.8)</td><td class="xxxr-borders shading">2 (0.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Herpes zoster infection<a href="#t2fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">0</td><td class="xxxx-borders">2 (0.5)</td><td class="xxxx-borders">1 (0.3)</td><td class="xxxx-borders">1 (0.4)</td><td class="xxxr-borders">5 (2.2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Cancer — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Basal-cell carcinoma</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (0.3)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">1 (0.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Rectal adenocarcinoma</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1 (0.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Adenocarcinoma of the colon</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (0.4)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Breast cancer</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (0.4)</td><td class="xxxr-borders shading">0</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Adverse events of special interest — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Bradycardia</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (0.5)</td><td class="xxxx-borders shading">3 (0.8)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Hypertension</td><td class="xxxx-borders">0</td><td class="xxxx-borders">6 (1.4)</td><td class="xxxx-borders">7 (1.9)</td><td class="xxxx-borders">3 (1.3)</td><td class="xxxr-borders">4 (1.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Hypertensive crisis</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (0.2)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (0.4)</td><td class="xxxr-borders shading">1 (0.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Macular edema</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (0.2)</td><td class="xxxx-borders">1 (0.3)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">1 (0.4)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Laboratory assessments — no./total no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging13">Alanine aminotransferase</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">≥2×ULN</td><td class="xxxx-borders shading">2/216 (0.9)</td><td class="xxxx-borders shading">25/423 (5.9)</td><td class="xxxx-borders shading">17/359 (4.7)</td><td class="xxxx-borders shading">12/227 (5.3)</td><td class="xxxr-borders shading">32/230 (13.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">≥3×ULN</td><td class="xxxx-borders">1/216 (0.5)</td><td class="xxxx-borders">11/423 (2.6)</td><td class="xxxx-borders">7/359 (1.9)</td><td class="xxxx-borders">4/227 (1.8)</td><td class="xxxr-borders">7/230 (3.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">≥5×ULN</td><td class="xxxx-borders shading">1/216 (0.5)</td><td class="xxxx-borders shading">4/423 (0.9)</td><td class="xxxx-borders shading">2/359 (0.6)</td><td class="xxxx-borders shading">1/227 (0.4)</td><td class="xxxr-borders shading">2/230 (0.9)</td></tr><tr data-type="row"><td class="xxlx-borders hanging13">Absolute lymphocyte count</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">&lt;200 cells per mm<sup>3</sup></td><td class="xxxx-borders shading">0/209</td><td class="xxxx-borders shading">9/421 (2.1)</td><td class="xxxx-borders shading">3/360 (0.8)</td><td class="xxxx-borders shading">0/227</td><td class="xxxr-borders shading">5/230 (2.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging23" data-xml-align="left">&lt;500 cells per mm<sup>3</sup></td><td class="xbxx-borders">0/209</td><td class="xbxx-borders">113/421 (26.8)</td><td class="xbxx-borders">114/360 (31.7)</td><td class="xbxx-borders">4/227 (1.8)</td><td class="xbxr-borders">100/230 (43.5)</td></tr></tbody></table></div><figcaption><div class="caption">Safety Findings through the Final Safety Visit in the Induction and Maintenance Periods.<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">The final safety follow-up visit was scheduled to occur 90 days (within a window of ±10 days) after the final dose of ozanimod or placebo. ULN denotes upper limit of the normal range.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t2fn2" role="paragraph">The group names indicate whether the patients received ozanimod or placebo during the maintenance period only; all the patients in the maintenance period had received ozanimod during the induction period.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t2fn3" role="paragraph">The most frequent events were defined as those that occurred in at least 3% of the patients who received ozanimod during the induction or maintenance period.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t2fn4" role="paragraph">Laboratory values were flagged by the central laboratory if they fell outside the standard reference range. The investigator decided whether the laboratory value qualified as an adverse event.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t2fn5" role="paragraph">All the patients had documented presence of varicella–zoster virus IgG antibody or complete varicella–zoster vaccination at screening.</div></div></div></figcaption></figure></div><div role="paragraph">In this trial that required patients to have a documented presence of varicella–zoster virus IgG antibody or complete varicella–zoster vaccination, herpes zoster infection occurred in 3 of 796 ozanimod-treated patients (0.4%) during the induction period and in 5 of 230 (2.2%) during the maintenance period (these events did not lead to hospitalization). Herpes zoster infection did not occur in any patient who did not receive ozanimod.</div><div role="paragraph">The absolute lymphocyte count decreased by a mean of approximately 54% from baseline to week 10 in patients who received ozanimod. Absolute lymphocyte counts of less than 200 cells per cubic millimeter occurred in 1.1% of the patients who received ozanimod (in cohort 1 or 2) and in no patients who received placebo during the induction period. Throughout the 52-week trial, 17 patients had an absolute lymphocyte count of less than 200 cells per cubic millimeter, which subsequently increased and remained at a level at or above 200 cells per cubic millimeter during ozanimod treatment. No patient with a serious or opportunistic infection had an absolute lymphocyte count of less than 200 cells per cubic millimeter.</div><div role="paragraph"><span id="tint8" class="named-content" data-type="exam-tint" data-answer-ids="three-a">Bradycardia occurred more frequently with ozanimod therapy than with placebo during the induction period but not during the maintenance period.</span> No cases of second-degree type 2 atrioventricular block or third-degree atrioventricular block occurred. One patient receiving ozanimod had a hypertensive crisis on day 1 of the induction period; the event was moderate and resolved on the same day without treatment interruption. During the maintenance period, serious adverse events of hypertensive crisis occurred in 1 patient each in the ozanimod group and the placebo group; neither event resulted in discontinuation of the trial regimen.</div><div role="paragraph"><span id="tint9" class="named-content" data-type="exam-tint" data-answer-ids="three-b three-c">Elevated liver aminotransferase levels were more common with ozanimod therapy than with placebo. No patients met Hy’s law criteria suggestive of drug-induced liver injury or had severe liver injury. Abnormal liver-function tests led to the discontinuation of ozanimod therapy in 3 of 796 patients (0.4%) in the induction period and in 1 of 230 patients (0.4%) in the maintenance period. Macular edema occurred in 3 patients receiving ozanimod; all cases resolved after treatment discontinuation (<a href="#t2">Table 2</a>).</span> Cancer was diagnosed in 1 patient who received ozanimod during the induction period (basal-cell carcinoma). In the maintenance period, cancer was diagnosed in 4 patients (basal-cell carcinoma and rectal adenocarcinoma in 1 patient each who received ozanimod during the induction and maintenance periods, and adenocarcinoma of the colon and breast cancer in 1 patient each who received ozanimod during the induction period and placebo during the maintenance period) (see the <a href="#ap2">Supplementary Appendix</a>).</div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph">The results of this phase 3 trial showed that a once-daily oral formulation of ozanimod, an S1P receptor modulator, provided clinical efficacy in patients with moderately to severely active ulcerative colitis. Treatment with ozanimod led to significant improvements, as compared with placebo, in the incidence of clinical remission (primary end point) and in all key secondary clinical, endoscopic, and histologic end points at weeks 10 and 52. These results were observed in patients with active disease that had been inadequately controlled by conventional agents, as determined on the basis of required concomitant therapy with aminosalicylates or glucocorticoids at trial entry.</div><div role="paragraph">Cancer, opportunistic infection, and macular edema were observed in patients who received ozanimod, but the incidences were low. Patients were excluded from the trial if they had macular edema at baseline or if they did not have immunity to varicella–zoster virus or had not received vaccination against varicella–zoster virus. Nonserious infections were more common with ozanimod than with placebo during the maintenance phase of the trial. The incidences of elevated alanine aminotransferase levels were higher among patients who received ozanimod than among those who received placebo. Liver events were mostly mild or moderate in severity and led to the discontinuation of the trial regimen in less than 1% of the patients. The absence of clinically significant bradycardia or cardiac conduction abnormalities may have been due to mitigation by the 7-day dose-escalation schedule.<sup><a href="#core-r13" role="doc-biblioref" data-xml-rid="r13 r14 r15 r24 r25 r26" id="body-ref-r26" href-manipulated="true">13–15,24–26</a></sup> It should be noted that the eligibility criteria for this trial excluded patients with conditions such as recent myocardial infarction, unstable angina or other clinically significant cardiovascular disease, or active or chronic infection. Overall, our results were consistent with safety findings that have previously been reported regarding ozanimod therapy in phase 3 trials involving patients with multiple sclerosis.<sup><a href="#core-r12" role="doc-biblioref" data-xml-rid="r12 r14 r15" id="body-ref-r15-3" href-manipulated="true">12,14,15</a></sup></div><div role="paragraph">Our trial design was informed by the increasing use of rigorous therapeutic targets beyond symptom control and endoscopic improvement in patients with ulcerative colitis, such as mucosal healing (requiring both endoscopic and histologic improvement) and reduced use of glucocorticoids.<sup><a href="#core-r27" role="doc-biblioref" data-xml-rid="r27 r28 r29 r30" id="body-ref-r30-1" href-manipulated="true">27-30</a></sup> For example, we required that the definition of mucosal healing include the absence of mucosal neutrophils, which has been associated with a reduced incidence of colectomy, hospitalization, and glucocorticoid use.<sup><a href="#core-r30" role="doc-biblioref" data-xml-rid="r30 r31" id="body-ref-r31" href-manipulated="true">30,31</a></sup> We also defined glucocorticoid-free remission as clinical remission at week 52 without glucocorticoid use for at least 12 weeks because relapse within 12 weeks after the discontinuation of glucocorticoid therapy is a defining characteristic of patients with ulcerative colitis in whom the glucocorticoid dose cannot be reduced beyond a certain threshold without relapse occurring.<sup><a href="#core-r32" role="doc-biblioref" data-xml-rid="r32" id="body-ref-r32" href-manipulated="true" aria-label="Reference 32">32</a></sup></div><div role="paragraph">A potential limitation of this trial is that the trial population may not be representative of the broader patient population in a routine clinical setting. Another limitation is the lack of long-term data; the open-label extension phase of this trial is ongoing.</div><div role="paragraph">In this phase 3 trial, we found that ozanimod was more effective than placebo as induction and maintenance therapy in patients with moderately to severely active ulcerative colitis.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="published/updated" role="paragraph">This article was updated on October 8, 2021, at NEJM.org.</div><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by Bristol Myers Squibb.</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank the patients and trial site personnel for their involvement; and Traci Stuve, M.A., of Peloton Advantage, an OPEN Health company, for providing writing assistance with an earlier version of the manuscript, with funding from Bristol Myers Squibb.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa2033617_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2033617/suppl_file/nejmoa2033617_protocol.pdf" download="nejmoa2033617_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2033617_protocol.pdf" data-doi="10.1056/NEJMoa2033617">Download</a></li><li>7.89 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa2033617_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2033617/suppl_file/nejmoa2033617_appendix.pdf" download="nejmoa2033617_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2033617_appendix.pdf" data-doi="10.1056/NEJMoa2033617">Download</a></li><li>946.66 KB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa2033617_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2033617/suppl_file/nejmoa2033617_disclosures.pdf" download="nejmoa2033617_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2033617_disclosures.pdf" data-doi="10.1056/NEJMoa2033617">Download</a></li><li>803.96 KB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa2033617_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2033617/suppl_file/nejmoa2033617_data-sharing.pdf" download="nejmoa2033617_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2033617_data-sharing.pdf" data-doi="10.1056/NEJMoa2033617">Download</a></li><li>74.69 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Lee SH, Kwon JE, Cho M-L. Immunological pathogenesis of inflammatory bowel disease. <em>Intest Res</em> 2018;16:26-42.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.5217/ir.2018.16.1.26" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29422795/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000429312200004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Immunological+pathogenesis+of+inflammatory+bowel+disease.&amp;publication_year=2018&amp;journal=Intest+Res&amp;pages=26-42&amp;doi=10.5217%2Fir.2018.16.1.26&amp;pmid=29422795" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. <em>Am J Gastroenterol</em> 2019;114:384-413.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r2" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.14309/ajg.0000000000000152" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30840605/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000463159300008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=ACG+clinical+guideline%3A+ulcerative+colitis+in+adults.&amp;publication_year=2019&amp;journal=Am+J+Gastroenterol&amp;pages=384-413&amp;doi=10.14309%2Fajg.0000000000000152&amp;pmid=30840605" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r2" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r2-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] with moderate, but not severe, disease. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] are not recommended as maintenance therapy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r2-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] and that have durable efficacy. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">D’Haens G. Systematic review: second-generation vs. conventional corticosteroids for induction of remission in ulcerative colitis. <em>Aliment Pharmacol Ther</em> 2016;44:1018-1029.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/apt.13803" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27650488/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000387596600002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Systematic+review%3A+second-generation+vs.+conventional+corticosteroids+for+induction+of+remission+in+ulcerative+colitis.&amp;publication_year=2016&amp;journal=Aliment+Pharmacol+Ther&amp;pages=1018-1029&amp;doi=10.1111%2Fapt.13803&amp;pmid=27650488" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Bianchi Porro G, Cassinotti A, Ferrara E, Maconi G, Ardizzone S. The management of steroid dependency in ulcerative colitis. <em>Aliment Pharmacol Ther</em> 2007;26:779-794.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.1365-2036.2007.03334.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17767462/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000249130100002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+management+of+steroid+dependency+in+ulcerative+colitis.&amp;publication_year=2007&amp;journal=Aliment+Pharmacol+Ther&amp;pages=779-794&amp;doi=10.1111%2Fj.1365-2036.2007.03334.x&amp;pmid=17767462" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Gordon JP, McEwan PC, Maguire A, Sugrue DM, Puelles J. Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn’s disease: a systematic review and clinician surveys. <em>Eur J Gastroenterol Hepatol</em> 2015;27:804-812.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/MEG.0000000000000378" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25933126/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000356588500007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Characterizing+unmet+medical+need+and+the+potential+role+of+new+biologic+treatment+options+in+patients+with+ulcerative+colitis+and+Crohn%E2%80%99s+disease%3A+a+systematic+review+and+clinician+surveys.&amp;publication_year=2015&amp;journal=Eur+J+Gastroenterol+Hepatol&amp;pages=804-812&amp;doi=10.1097%2FMEG.0000000000000378&amp;pmid=25933126" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Xeljanz. New York: Pfizer Labs, 2018 (package insert).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Xeljanz&amp;publication_year=2018" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Scott FL, Clemons B, Brooks J, et al. Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity. <em>Br J Pharmacol</em> 2016;173:1778-1792.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r9"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/bph.13476" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26990079/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000377252100006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Ozanimod+%28RPC1063%29+is+a+potent+sphingosine-1-phosphate+receptor-1+%28S1P1%29+and+receptor-5+%28S1P5%29+agonist+with+autoimmune+disease-modifying+activity.&amp;publication_year=2016&amp;journal=Br+J+Pharmacol&amp;pages=1778-1792&amp;doi=10.1111%2Fbph.13476&amp;pmid=26990079" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Tran JQ, Zhang P, Surapaneni S, Selkirk J, Yan G, Palmisano M. Absorption, metabolism, and excretion, in vitro pharmacology, and clinical pharmacokinetics of ozanimod, a novel sphingosine 1-phosphate receptor agonist. Presented at the Annual Meeting of the European Committee for Treatment and Research in Multiple Sclerosis, Stockholm, September 11–13, 2019. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r9"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Absorption%2C+metabolism%2C+and+excretion%2C+in+vitro+pharmacology%2C+and+clinical+pharmacokinetics+of+ozanimod%2C+a+novel+sphingosine+1-phosphate+receptor+agonist&amp;publication_year=2019" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. <em>Nature</em> 2004;427:355-360.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r9"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nature02284" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/14737169/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000188266200042" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Lymphocyte+egress+from+thymus+and+peripheral+lymphoid+organs+is+dependent+on+S1P+receptor+1.&amp;publication_year=2004&amp;journal=Nature&amp;pages=355-360&amp;doi=10.1038%2Fnature02284&amp;pmid=14737169" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Sandborn WJ, Feagan BG, Wolf DC, et al. Ozanimod induction and maintenance treatment for ulcerative colitis. <em>N Engl J Med</em> 2016;374:1754-1762.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r10" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_11_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2033617&amp;key=10.1056%2FNEJMoa1513248&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27144850/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000375341500008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Ozanimod+induction+and+maintenance+treatment+for+ulcerative+colitis.&amp;publication_year=2016&amp;journal=N+Engl+J+Med&amp;pages=1754-1762&amp;doi=10.1056%2FNEJMoa1513248&amp;pmid=27144850" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r10" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] with moderate-to-severe ulcerative colitis. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r15-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] were monitored in the clinical trials. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Feagan BG, Sandborn WJ, Danese S, et al. Ozanimod induction therapy for patients with moderate to severe Crohn’s disease: a single-arm, phase 2, prospective observer-blinded endpoint study. <em>Lancet Gastroenterol Hepatol</em> 2020;5:819-828.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r11" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2468-1253(20)30188-6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32553149/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000562267100020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Ozanimod+induction+therapy+for+patients+with+moderate+to+severe+Crohn%E2%80%99s+disease%3A+a+single-arm%2C+phase+2%2C+prospective+observer-blinded+endpoint+study.&amp;publication_year=2020&amp;journal=Lancet+Gastroenterol+Hepatol&amp;pages=819-828&amp;doi=10.1016%2FS2468-1253%2820%2930188-6&amp;pmid=32553149" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r11" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r11-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] therapy in patients with Crohn’s disease. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r15-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] were monitored in the clinical trials. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Lamb YN. Ozanimod: first approval. <em>Drugs</em> 2020;80:841-848.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r12" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s40265-020-01319-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32385738/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000531127700001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Ozanimod%3A+first+approval.&amp;publication_year=2020&amp;journal=Drugs&amp;pages=841-848&amp;doi=10.1007%2Fs40265-020-01319-7&amp;pmid=32385738" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r12" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r15-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] were monitored in the clinical trials. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r15-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] involving patients with multiple sclerosis. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Selmaj KW, Steinman L, Comi G, et al. Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis in DAYBREAK: an open-label extension study of ozanimod phase 1−3 trials. Presented at the Triennial Joint Meeting of the European and Americas Committees for Treatment and Research in Multiple Sclerosis (MSVirtual2020), September 11–13, 2020.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r13" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Long-term+safety+and+efficacy+of+ozanimod+in+relapsing+multiple+sclerosis+in+DAYBREAK%3A+an+open-label+extension+study+of+ozanimod+phase+1%E2%88%923+trials&amp;publication_year=2020" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r13" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r15-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] were monitored in the clinical trials. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] by the 7-day dose-escalation schedule. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Comi G, Kappos L, Selmaj KW, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. <em>Lancet Neurol</em> 2019;18:1009-1020.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r14" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1474-4422(19)30239-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31492651/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000489517000014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety+and+efficacy+of+ozanimod+versus+interferon+beta-1a+in+relapsing+multiple+sclerosis+%28SUNBEAM%29%3A+a+multicentre%2C+randomised%2C+minimum+12-month%2C+phase+3+trial.&amp;publication_year=2019&amp;journal=Lancet+Neurol&amp;pages=1009-1020&amp;doi=10.1016%2FS1474-4422%2819%2930239-X&amp;pmid=31492651" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r14" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r15-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] were monitored in the clinical trials. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] by the 7-day dose-escalation schedule. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r15-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] involving patients with multiple sclerosis. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Cohen JA, Comi G, Selmaj KW, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. <em>Lancet Neurol</em> 2019;18:1021-1033.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r15" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1474-4422(19)30238-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31492652/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000489517000015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety+and+efficacy+of+ozanimod+versus+interferon+beta-1a+in+relapsing+multiple+sclerosis+%28RADIANCE%29%3A+a+multicentre%2C+randomised%2C+24-month%2C+phase+3+trial.&amp;publication_year=2019&amp;journal=Lancet+Neurol&amp;pages=1021-1033&amp;doi=10.1016%2FS1474-4422%2819%2930238-8&amp;pmid=31492652" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r15" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r15-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] were monitored in the clinical trials. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] by the 7-day dose-escalation schedule. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r15-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] involving patients with multiple sclerosis. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">Lewis JD, Chuai S, Nessel L, Lichtenstein GR, Aberra FN, Ellenberg JH. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. <em>Inflamm Bowel Dis</em> 2008;14:1660-1666.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/ibd.20520" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18623174/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000261541200006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Use+of+the+noninvasive+components+of+the+Mayo+score+to+assess+clinical+response+in+ulcerative+colitis.&amp;publication_year=2008&amp;journal=Inflamm+Bowel+Dis&amp;pages=1660-1666&amp;doi=10.1002%2Fibd.20520&amp;pmid=18623174" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">Tran JQ, Hartung JP, Peach RJ, et al. Results from the first-in-human study with ozanimod, a novel, selective sphingosine-1-phosphate receptor modulator. <em>J Clin Pharmacol</em> 2017;57:988-996.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/jcph.887" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28398597/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000407044800006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Results+from+the+first-in-human+study+with+ozanimod%2C+a+novel%2C+selective+sphingosine-1-phosphate+receptor+modulator.&amp;publication_year=2017&amp;journal=J+Clin+Pharmacol&amp;pages=988-996&amp;doi=10.1002%2Fjcph.887&amp;pmid=28398597" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">Brossard P, Derendorf H, Xu J, Maatouk H, Halabi A, Dingemanse J. Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study. <em>Br J Clin Pharmacol</em> 2013;76:888-896.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/bcp.12129" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23594176/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000330178900006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pharmacokinetics+and+pharmacodynamics+of+ponesimod%2C+a+selective+S1P1+receptor+modulator%2C+in+the+first-in-human+study.&amp;publication_year=2013&amp;journal=Br+J+Clin+Pharmacol&amp;pages=888-896&amp;doi=10.1111%2Fbcp.12129&amp;pmid=23594176" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content">Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. <em>N Engl J Med</em> 1987;317:1625-1629.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r19"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_20_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2033617&amp;key=10.1056%2FNEJM198712243172603&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/3317057/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1987L364400003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Coated+oral+5-aminosalicylic+acid+therapy+for+mildly+to+moderately+active+ulcerative+colitis%3A+a+randomized+study.&amp;publication_year=1987&amp;journal=N+Engl+J+Med&amp;pages=1625-1629&amp;doi=10.1056%2FNEJM198712243172603&amp;pmid=3317057" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content">Geboes K, Riddell R, Ost A, Jensfelt B, Persson T, Löfberg R. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. <em>Gut</em> 2000;47:404-409.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/gut.47.3.404" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/10940279/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000088869800019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+reproducible+grading+scale+for+histological+assessment+of+inflammation+in+ulcerative+colitis.&amp;publication_year=2000&amp;journal=Gut&amp;pages=404-409&amp;doi=10.1136%2Fgut.47.3.404&amp;pmid=10940279" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">Fragoso YD. Multiple sclerosis treatment with fingolimod: profile of non-cardiologic adverse events. <em>Acta Neurol Belg</em> 2017;117:821-827.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s13760-017-0794-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28528469/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000414387200002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Multiple+sclerosis+treatment+with+fingolimod%3A+profile+of+non-cardiologic+adverse+events.&amp;publication_year=2017&amp;journal=Acta+Neurol+Belg&amp;pages=821-827&amp;doi=10.1007%2Fs13760-017-0794-7&amp;pmid=28528469" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="r22" class="citations"><div class="citation"><div class="citation-content">Kappos L, Bar-Or A, Cree BAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. <em>Lancet</em> 2018;391:1263-1273.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(18)30475-6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29576505/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000428791600025" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Siponimod+versus+placebo+in+secondary+progressive+multiple+sclerosis+%28EXPAND%29%3A+a+double-blind%2C+randomised%2C+phase+3+study.&amp;publication_year=2018&amp;journal=Lancet&amp;pages=1263-1273&amp;doi=10.1016%2FS0140-6736%2818%2930475-6&amp;pmid=29576505" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="r23" class="citations"><div class="citation"><div class="citation-content">Rubin DB. Inference and missing data. <em>Biometrika</em> 1976;63:581-592.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/biomet/63.3.581" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1976CP66700021" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Inference+and+missing+data.&amp;publication_year=1976&amp;journal=Biometrika&amp;pages=581-592&amp;doi=10.1093%2Fbiomet%2F63.3.581" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="r24" class="citations"><div class="citation"><div class="citation-content">Zeposia. Princeton, NJ: Bristol-Myers Squibb, 2020 (package insert).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Zeposia&amp;publication_year=2020" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="r25" class="citations"><div class="citation"><div class="citation-content">Zeposia. Utrecht, the Netherlands: Celgene Distribution B.V., 2020 (summary of product characteristics).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Zeposia&amp;publication_year=2020" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="r26" class="citations"><div class="citation"><div class="citation-content">Cohen JA, Arnold DL, Comi G, et al. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial. <em>Lancet Neurol</em> 2016;15:373-381.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1474-4422(16)00018-1" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26879276/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000371974000017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety+and+efficacy+of+the+selective+sphingosine+1-phosphate+receptor+modulator+ozanimod+in+relapsing+multiple+sclerosis+%28RADIANCE%29%3A+a+randomised%2C+placebo-controlled%2C+phase+2+trial.&amp;publication_year=2016&amp;journal=Lancet+Neurol&amp;pages=373-381&amp;doi=10.1016%2FS1474-4422%2816%2900018-1&amp;pmid=26879276" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="r27" class="citations"><div class="citation"><div class="citation-content">Danese S, Roda G, Peyrin-Biroulet L. Evolving therapeutic goals in ulcerative colitis: towards disease clearance. <em>Nat Rev Gastroenterol Hepatol</em> 2020;17:1-2.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r30-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41575-019-0211-1" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31520081/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000504707500001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Evolving+therapeutic+goals+in+ulcerative+colitis%3A+towards+disease+clearance.&amp;publication_year=2020&amp;journal=Nat+Rev+Gastroenterol+Hepatol&amp;pages=1-2&amp;doi=10.1038%2Fs41575-019-0211-1&amp;pmid=31520081" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="r28" class="citations"><div class="citation"><div class="citation-content">Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. <em>Gastroenterology</em> 2011;141:1194-1201.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r30-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1053/j.gastro.2011.06.054" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21723220/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000295593700026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Early+mucosal+healing+with+infliximab+is+associated+with+improved+long-term+clinical+outcomes+in+ulcerative+colitis.&amp;publication_year=2011&amp;journal=Gastroenterology&amp;pages=1194-1201&amp;doi=10.1053%2Fj.gastro.2011.06.054&amp;pmid=21723220" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="r29" class="citations"><div class="citation"><div class="citation-content">Pai RK, Jairath V, Vande Casteele N, Rieder F, Parker CE, Lauwers GY. The emerging role of histologic disease activity assessment in ulcerative colitis. <em>Gastrointest Endosc</em> 2018;88:887-898.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r30-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.gie.2018.08.018" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30142351/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000450323100001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+emerging+role+of+histologic+disease+activity+assessment+in+ulcerative+colitis.&amp;publication_year=2018&amp;journal=Gastrointest+Endosc&amp;pages=887-898&amp;doi=10.1016%2Fj.gie.2018.08.018&amp;pmid=30142351" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="r30" class="citations"><div class="citation"><div class="citation-content">Jangi S, Yoon H, Dulai PS, et al. Predictors and outcomes of histological remission in ulcerative colitis treated to endoscopic healing. <em>Aliment Pharmacol Ther</em> 2020;52:1008-1016.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r30" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/apt.16026" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33119168/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000557256100001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Predictors+and+outcomes+of+histological+remission+in+ulcerative+colitis+treated+to+endoscopic+healing.&amp;publication_year=2020&amp;journal=Aliment+Pharmacol+Ther&amp;pages=1008-1016&amp;doi=10.1111%2Fapt.16026&amp;pmid=33119168" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r30" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r30-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and reduced use of glucocorticoids. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r31" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] hospitalization, and glucocorticoid use. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="r31" class="citations"><div class="citation"><div class="citation-content">Pai RK, Hartman DJ, Rivers CR, et al. Complete resolution of mucosal neutrophils associates with improved long-term clinical outcomes of patients with ulcerative colitis. <em>Clin Gastroenterol Hepatol</em> 2020;18(11):2510.e5-2517.e5.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.cgh.2019.12.011" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31843598/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000572816500002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Complete+resolution+of+mucosal+neutrophils+associates+with+improved+long-term+clinical+outcomes+of+patients+with+ulcerative+colitis.&amp;publication_year=2020&amp;journal=Clin+Gastroenterol+Hepatol&amp;pages=2510.e5-2517.e5&amp;doi=10.1016%2Fj.cgh.2019.12.011&amp;pmid=31843598" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">32.</div><div id="r32" class="citations"><div class="citation"><div class="citation-content">Stange EF, Travis SPL, Vermeire S, et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. <em>J Crohns Colitis</em> 2008;2:1-23.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r32"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.crohns.2007.11.001" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21172194/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000261637100001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=European+evidence-based+consensus+on+the+diagnosis+and+management+of+ulcerative+colitis%3A+definitions+and+diagnosis.&amp;publication_year=2008&amp;journal=J+Crohns+Colitis&amp;pages=1-23&amp;doi=10.1016%2Fj.crohns.2007.11.001&amp;pmid=21172194" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/385/14"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">385</span></span> • <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">14</span></span> • <span property="datePublished">September 30, 2021</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">1280</span>-<span property="pageEnd">1291</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright © 2021 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section data-translation="YXQYoa2033617" class="core-component-translation"><h4>Translation</h4><div role="paragraph"><a target="_blank" href="https://nejmqianyan.cn/article/YXQYoa2033617?sg=AbW1N">Chinese Translation 中文翻译</a></div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: September 29, 2021</div><div><b class="core-label">Published in issue</b>: September 30, 2021</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/inflammatory-bowel-disease" alt="View article keyword Inflammatory Bowel Disease" data-interactiontype="article_recirculation_click">Inflammatory Bowel Disease</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">William J.</span> <span property="familyName">Sandborn</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Brian G.</span> <span property="familyName">Feagan</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Geert</span> <span property="familyName">D’Haens</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Douglas C.</span> <span property="familyName">Wolf</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0003-0330-8919" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0003-0330-8919</a></span>, <span property="author" typeof="Person"><span property="givenName">Igor</span> <span property="familyName">Jovanovic</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Stephen B.</span> <span property="familyName">Hanauer</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Subrata</span> <span property="familyName">Ghosh</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">AnnKatrin</span> <span property="familyName">Petersen</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Steven Y.</span> <span property="familyName">Hua</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Ji Hwan</span> <span property="familyName">Lee</span>, <span property="honorificSuffix">M.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Lorna</span> <span property="familyName">Charles</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Denesh</span> <span property="familyName">Chitkara</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Keith</span> <span property="familyName">Usiskin</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Jean-Frederic</span> <span property="familyName">Colombel</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Loren</span> <span property="familyName">Laine</span>, <span property="honorificSuffix">M.D.</span></span>, and <span property="author" typeof="Person"><span property="givenName">Silvio</span> <span property="familyName">Danese</span>, <span property="honorificSuffix">M.D.</span></span>, for <span property="author" typeof="Person">the True North Study Group<sup><a href="#fn1" role="doc-noteref">*</a></sup></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From the University of California San Diego, La Jolla (W.J.S.); Western University, London, ON, Canada (B.G.F.); the Inflammatory Bowel Disease Center, Academic Medical Center, Amsterdam (G.D.); the Center for Crohn’s Disease and Ulcerative Colitis, Atlanta Gastroenterology Associates, Atlanta (D.C.W.); the Division of Gastroenterology, University Hospital Medical Center Bežanijska Kosa, Belgrade, Serbia (I.J.); the Feinberg School of Medicine, Chicago (S.B.H.); APC Microbiome Ireland, College of Medicine and Health, University College Cork, Cork, Ireland (S.G.); Bristol Myers Squibb, Princeton, NJ (A.P., S.Y.H., J.H.L., L.C., D.C., K.U.); the Department of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York (J.-F.C.); Yale School of Medicine, New Haven, and the Veterans Affairs Connecticut Healthcare System, West Haven — both in Connecticut (L.L.); and IRCCS Humanitas Research Hospital and University Vita-Salute San Raffaele, Milan (S.D.).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Address reprint requests to Dr. Sandborn at the Division of Gastroenterology, University of California San Diego, 9500 Gilman Dr., La Jolla, CA 92093-0956, or at <a href="mailto:wsandborn@ucsd.edu">wsandborn@ucsd.edu</a>.</div><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="fn1" role="paragraph">A complete list of the members of the True North Study Group is provided in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org.</div></div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">378</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa2033617" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="bca9ee77-a799-0f57-6c51-d1e2ffc82e3f"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=114241070" style="display:inline-block;">
                <img alt="Article has an altmetric score of 225" src="https://badges.altmetric.com/?size=320&amp;score=225&amp;types=mabctfd1" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=114241070">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_bca9ee77-a799-0f57-6c51-d1e2ffc82e3f" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=114241070&amp;tab=news">
          Picked up by <b>22</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=114241070&amp;tab=blogs">
          Blogged by <b>3</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #9f79f2;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=114241070&amp;tab=policy-documents">
          Referenced in <b>1</b> policy sources
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=114241070&amp;tab=twitter">
          Posted by <b>76</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #f27700;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=114241070&amp;tab=patents">
          Referenced in <b>1</b> patents
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=114241070&amp;tab=facebook">
          On <b>2</b> Facebook pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #F4006E;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=114241070&amp;tab=research-highlights">
          Highlighted by <b>1</b> platforms
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #A1E3E4;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=114241070&amp;tab=guidelines">
          Referenced in <b>1</b> clinical guideline sources
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>327</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d69ddb368cf227-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa2033617"> <input type="hidden" name="downloadFileName" value="csp_385_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2021.385.issue-14%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2033617%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="378" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Massimo C. Fantini, </li><li class="list-inline-item cited-by__entry__author">Diego Centonze, </li><li class="list-inline-item cited-by__entry__author">Giovanni Giacobazzi, </li><li class="list-inline-item cited-by__entry__author">Silvia Benemei, </li><li class="list-inline-item cited-by__entry__author">Emanuele Romeo, </li></ul><span class="cited-by__entry__title">Sphingosine‐1‐Phosphate Receptor Modulators for the Treatment of Ulcerative Colitis: A Narrative Review Focusing on Safety, </span><span class="cited-by__entry__series-title">United European Gastroenterology Journal, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1002/ueg2.70026" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1002/ueg2.70026</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1002/ueg2.70026" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Nadia Eden, </li><li class="list-inline-item cited-by__entry__author">Elizabeth Gaunt, </li><li class="list-inline-item cited-by__entry__author">Elaine Ming San Ong, </li><li class="list-inline-item cited-by__entry__author">Kassem Sharif, </li><li class="list-inline-item cited-by__entry__author">Christian Selinger, </li></ul><span class="cited-by__entry__title">The Role of Novel Small Molecule Drugs in the Management of Inflammatory Bowel Disease, </span><span class="cited-by__entry__series-title">British Journal of Hospital Medicine, </span><span class="cited-by__entry__page-range">(1-14), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.12968/hmed.2024.0798" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.12968/hmed.2024.0798</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.12968/hmed.2024.0798" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Jiayan Hu, </li><li class="list-inline-item cited-by__entry__author">Wenting Wang, </li><li class="list-inline-item cited-by__entry__author">Muyuan Wang, </li><li class="list-inline-item cited-by__entry__author">Chunye Wu, </li><li class="list-inline-item cited-by__entry__author">Yao Jiao, </li><li class="list-inline-item cited-by__entry__author">Yitong Li, </li><li class="list-inline-item cited-by__entry__author">Wenji Zhang, </li><li class="list-inline-item cited-by__entry__author">Chengtao Liang, </li><li class="list-inline-item cited-by__entry__author">Zhengdao Lin, </li><li class="list-inline-item cited-by__entry__author">Yitong Yu, </li><li class="list-inline-item cited-by__entry__author">Junxiang Li, </li><li class="list-inline-item cited-by__entry__author">Tangyou Mao, </li></ul><span class="cited-by__entry__title">Immunological pathogenesis of inflammatory bowel disease: focus on tissue resident memory T cells, </span><span class="cited-by__entry__series-title">Frontiers in Immunology, </span><span class="cited-by__entry__volume"><strong>16</strong>, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.3389/fimmu.2025.1591584" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.3389/fimmu.2025.1591584</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.3389/fimmu.2025.1591584" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Xin Yao, </li><li class="list-inline-item cited-by__entry__author">Kaiming Ma, </li><li class="list-inline-item cited-by__entry__author">Yangzhuangzhuang Zhu, </li><li class="list-inline-item cited-by__entry__author">Siyan Cao, </li></ul><span class="cited-by__entry__title">Innate Lymphoid Cells in Inflammatory Bowel Disease, </span><span class="cited-by__entry__series-title">Cells, </span><span class="cited-by__entry__volume"><strong>14</strong>, </span><span class="cited-by__entry__issue">11, </span><span class="cited-by__entry__page-range">(825), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.3390/cells14110825" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.3390/cells14110825</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.3390/cells14110825" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">David T. Rubin, </li><li class="list-inline-item cited-by__entry__author">Ashwin N. Ananthakrishnan, </li><li class="list-inline-item cited-by__entry__author">Corey A. Siegel, </li><li class="list-inline-item cited-by__entry__author">Edward L. Barnes, </li><li class="list-inline-item cited-by__entry__author">Millie D. Long, </li></ul><span class="cited-by__entry__title">ACG Clinical Guideline Update: Ulcerative Colitis in Adults, </span><span class="cited-by__entry__series-title">American Journal of Gastroenterology, </span><span class="cited-by__entry__volume"><strong>120</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(1187-1224), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.14309/ajg.0000000000003463" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.14309/ajg.0000000000003463</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.14309/ajg.0000000000003463" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Yusuf A. Hannun, </li><li class="list-inline-item cited-by__entry__author">Alfred H. Merrill, </li><li class="list-inline-item cited-by__entry__author">Chiara Luberto, </li></ul><span class="cited-by__entry__title">The bioactive sphingolipid playbook. A primer for the uninitiated as well as sphingolipidologists, </span><span class="cited-by__entry__series-title">Journal of Lipid Research, </span><span class="cited-by__entry__volume"><strong>66</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(100813), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.jlr.2025.100813" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jlr.2025.100813</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jlr.2025.100813" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Magdalena Iwan, </li><li class="list-inline-item cited-by__entry__author">Weronika Wójtowicz, </li><li class="list-inline-item cited-by__entry__author">Jakub Milczarek, </li><li class="list-inline-item cited-by__entry__author">Natalia Wyroba, </li><li class="list-inline-item cited-by__entry__author">Zuzanna Wydrych, </li><li class="list-inline-item cited-by__entry__author">Olga Falger, </li><li class="list-inline-item cited-by__entry__author">Michalina Rzepka, </li><li class="list-inline-item cited-by__entry__author">Tomasz Chmiela, </li><li class="list-inline-item cited-by__entry__author">Mateusz Toś, </li><li class="list-inline-item cited-by__entry__author">Joanna Siuda, </li></ul><span class="cited-by__entry__title">The Relationship Between Autoimmune Disorders and Multiple Sclerosis: Clinical Insights and Therapeutic Approaches, </span><span class="cited-by__entry__series-title">Brain Sciences, </span><span class="cited-by__entry__volume"><strong>15</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(588), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.3390/brainsci15060588" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.3390/brainsci15060588</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.3390/brainsci15060588" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Brigida Barberio, </li><li class="list-inline-item cited-by__entry__author">David J. Gracie, </li><li class="list-inline-item cited-by__entry__author">Christopher J. Black, </li><li class="list-inline-item cited-by__entry__author">Alexander C. Ford, </li></ul><span class="cited-by__entry__title">Network Meta‐Analysis: Efficacy of Biological Therapies and Small Molecules as Maintenance Therapy in Ulcerative Colitis, </span><span class="cited-by__entry__series-title">Alimentary Pharmacology &amp; Therapeutics, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1111/apt.70209" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1111/apt.70209</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1111/apt.70209" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Guoqing Li, </li><li class="list-inline-item cited-by__entry__author">Yuxuan Wan, </li><li class="list-inline-item cited-by__entry__author">Alan Jiao, </li><li class="list-inline-item cited-by__entry__author">Ke Jiang, </li><li class="list-inline-item cited-by__entry__author">Gaoyuan Cui, </li><li class="list-inline-item cited-by__entry__author">Jinxin Tang, </li><li class="list-inline-item cited-by__entry__author">Simin Yu, </li><li class="list-inline-item cited-by__entry__author">Zhengang Hu, </li><li class="list-inline-item cited-by__entry__author">Songfeng Zhao, </li><li class="list-inline-item cited-by__entry__author">Zhenjie Yi, </li><li class="list-inline-item cited-by__entry__author">Lifu Long, </li><li class="list-inline-item cited-by__entry__author">Yang Yang, </li><li class="list-inline-item cited-by__entry__author">Xuehao Cui, </li><li class="list-inline-item cited-by__entry__author">Chunrun Qu, </li></ul><span class="cited-by__entry__title">Breaking Boundaries: Chronic Diseases and the Frontiers of Immune Microenvironments, </span><span class="cited-by__entry__series-title">Med Research, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1002/mdr2.70007" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1002/mdr2.70007</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1002/mdr2.70007" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Xin Yi Choon, </li><li class="list-inline-item cited-by__entry__author">Jie Han Yeo, </li><li class="list-inline-item cited-by__entry__author">Christopher White, </li><li class="list-inline-item cited-by__entry__author">Esha Sharma, </li><li class="list-inline-item cited-by__entry__author">Mark A. Samaan, </li></ul><span class="cited-by__entry__title">The Current Sphingosine 1 Phosphate Receptor Modulators in the Management of Ulcerative Colitis, </span><span class="cited-by__entry__series-title">Journal of Clinical Medicine, </span><span class="cited-by__entry__volume"><strong>14</strong>, </span><span class="cited-by__entry__issue">10, </span><span class="cited-by__entry__page-range">(3475), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.3390/jcm14103475" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.3390/jcm14103475</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.3390/jcm14103475" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2021.385.issue-14%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2033617%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2033617" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2033617" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2033617.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2033617_f1.jpg"><img src="/cms/10.1056/NEJMoa2033617/asset/22eb968b-c730-4e0c-848f-ab35af3719fb/assets/images/large/nejmoa2033617_f1.jpg" height="1894" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Randomization and Follow-up of the Patients in the Induction and Maintenance Periods.</div><div class="notes"><div role="doc-footnote">The most common reasons for ineligibility were disease criteria not met (in 18.1% of the patients who underwent screening), a lack of documentation of varicella–zoster virus IgG antibodies or vaccination (in 5.7%), inability to provide informed consent or to comply with protocol assessments (in 4.6%), and presence of <i>Clostridium difficile</i> or other stool pathogens (in 3.7%). In cohort 1, patients were randomly assigned to receive ozanimod or placebo; once the percentage of patients with previous exposure to a tumor necrosis factor (TNF) antagonist reached 30%, subsequent patients with TNF antagonist exposure were assigned to cohort 2, in which they received open-label ozanimod. Clinical response was defined as a reduction of at least 3 points and of at least 30% from baseline in the total Mayo score or a reduction of at least 2 points and of at least 35% from baseline in the three-component Mayo score, plus a reduction of at least 1 point in the rectal-bleeding score or an absolute rectal-bleeding score of no more than 1 point. The total Mayo score is defined as the sum of the rectal-bleeding subscore, the stool-frequency subscore, the physician’s global assessment subscore, and the endoscopy subscore; overall scores range from 0 to 12 (with each subscore on a scale from 0 to 3), with higher scores indicating greater activity. The three-component Mayo score is defined as the sum of the rectal-bleeding subscore, the stool-frequency subscore, and the endoscopy subscore; overall scores range from 0 to 9 (with each subscore ranging from 0 to 3), with higher scores indicating greater activity.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2033617_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f2"><figure class="graphic"><a class="open-in-viewer" href="#f2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2033617_f2.jpg"><img src="/cms/10.1056/NEJMoa2033617/asset/2ac4695c-d58a-4392-87c7-951673283104/assets/images/large/nejmoa2033617_f2.jpg" height="1939" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Efficacy Results for Ozanimod as Induction and Maintenance Therapy, as Compared with Placebo (Modified Intention-to-Treat Population).</div><div class="notes"><div role="doc-footnote">Panel A shows the primary end point (shaded area) and key secondary end points from the induction period (cohort 1) at week 10, and Panel B the primary end point (shaded area) and key secondary end points from the maintenance period at week 52. Percentages of patients with each end point (as well as the numbers and total numbers of patients) are shown, and between-group differences are shown in percentage points with 95% confidence intervals (CI). End points are shown in the order from the hierarchical testing procedure. The modified intention-to-treat population included all patients who underwent randomization and received at least one dose of ozanimod or placebo. Analysis in the induction period was based on the two-sided Cochran–Mantel–Haenszel test and stratified according to glucocorticoid use at screening and previous use of a TNF antagonist. Analysis in the maintenance period was based on the two-sided Cochran–Mantel–Haenszel test and stratified according to clinical remission status at week 10 of the induction period and glucocorticoid use at week 10 of the induction period. Missing data were handled with the use of a “nonresponse” imputation.</div><div role="doc-footnote">Clinical remission was defined as a rectal-bleeding subscore of 0, a stool-frequency subscore of 1 or less (plus a ≥1-point reduction from baseline), and a mucosal endoscopy subscore of 1 or less, without friability. Clinical response was defined as a reduction in the three-component Mayo score of at least 2 points and at least 35% from baseline, as well as a reduction in the rectal-bleeding subscore of at least 1 point or an absolute rectal-bleeding subscore of 1 or less. Endoscopic improvement was defined as a mucosal endoscopy subscore of 1 or less, without friability. Mucosal healing was defined as endoscopic improvement plus histologic remission (i.e., a Geboes score of &lt;2.0 [on a scale from 0 to 5.4, with higher scores indicating more severe inflammation] and an absence of neutrophils in the epithelial crypts or lamina propria and no increase in eosinophils, no crypt destruction, and no erosions, ulcerations, or granulation tissue). Maintenance of remission was defined as clinical remission at 52 weeks in the subgroup of patients with remission at week 10. Glucocorticoid-free remission was defined as clinical remission at 52 weeks without receipt of glucocorticoids for at least 12 weeks. Durable remission was defined as remission at both weeks 10 and 52.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f2"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2033617_f2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2033617_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2033617/asset/c6154390-a71f-490a-b43b-58a97ed224c5/assets/images/large/nejmoa2033617_t1.jpg" height="2814" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders" colspan="2"><span>Cohort 1</span></th><th class="txxr-borders">Cohort 2</th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Placebo<br>(N=216)</th><th class="xxxx-borders">Ozanimod<br>(N=429)</th><th class="xxxr-borders">Ozanimod<br>(N=367)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Male sex — no. (%)</td><td class="xxxx-borders shading">143 (66.2)</td><td class="xxxx-borders shading">245 (57.1)</td><td class="xxxr-borders shading">214 (58.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Age — yr</td><td class="xxxx-borders">41.9±13.6</td><td class="xxxx-borders">41.4±13.5</td><td class="xxxr-borders">42.1±13.7</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Body-mass index<a href="#core-t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">25.1±4.5</td><td class="xxxx-borders shading">25.4±5.5</td><td class="xxxr-borders shading">25.9±5.8</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Time since diagnosis of ulcerative colitis — yr</td><td class="xxxx-borders">6.8±7.0</td><td class="xxxx-borders">6.9±6.6</td><td class="xxxr-borders">7.9±7.4</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Extent of disease — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Left side of colon</td><td class="xxxx-borders">134 (62.0)</td><td class="xxxx-borders">268 (62.5)</td><td class="xxxr-borders">237 (64.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Extensive</td><td class="xxxx-borders shading">82 (38.0)</td><td class="xxxx-borders shading">161 (37.5)</td><td class="xxxr-borders shading">130 (35.4)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Mayo score</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Total score<a href="#core-t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">8.9±1.4</td><td class="xxxx-borders shading">8.9±1.5</td><td class="xxxr-borders shading">9.1±1.5</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Three-component score<a href="#core-t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">6.6±1.2</td><td class="xxxx-borders">6.6±1.2</td><td class="xxxr-borders">6.8±1.3</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Fecal calprotectin — μg/g</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Median</td><td class="xxxx-borders">1350</td><td class="xxxx-borders">1080</td><td class="xxxr-borders">1260</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Interquartile range</td><td class="xxxx-borders shading">345–3075</td><td class="xxxx-borders shading">399–2532</td><td class="xxxr-borders shading">421–2881</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">C-reactive protein — mg/liter</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Median</td><td class="xxxx-borders shading">5.0</td><td class="xxxx-borders shading">4.0</td><td class="xxxr-borders shading">5.0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Interquartile range</td><td class="xxxx-borders">2.0–12.0</td><td class="xxxx-borders">1.0–9.0</td><td class="xxxr-borders">2.0–11.0</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Concomitant medication use — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Systemic glucocorticoid</td><td class="xxxx-borders">70 (32.4)</td><td class="xxxx-borders">119 (27.7)</td><td class="xxxr-borders">124 (33.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Budesonide</td><td class="xxxx-borders shading">13 (6.0)</td><td class="xxxx-borders shading">19 (4.4)</td><td class="xxxr-borders shading">23 (6.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Oral aminosalicylate</td><td class="xxxx-borders">182 (84.3)</td><td class="xxxx-borders">374 (87.2)</td><td class="xxxr-borders">315 (85.8)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Previous medication use</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Glucocorticoid — no. (%)</td><td class="xxxx-borders">162 (75.0)</td><td class="xxxx-borders">322 (75.1)</td><td class="xxxr-borders">286 (77.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Immunomodulator — no. (%)</td><td class="xxxx-borders shading">93 (43.1)</td><td class="xxxx-borders shading">174 (40.6)</td><td class="xxxr-borders shading">166 (45.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Oral aminosalicylate — no. (%)</td><td class="xxxx-borders">210 (97.2)</td><td class="xxxx-borders">418 (97.4)</td><td class="xxxr-borders">362 (98.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Vedolizumab — no. (%)</td><td class="xxxx-borders shading">38 (17.6)</td><td class="xxxx-borders shading">71 (16.6)</td><td class="xxxr-borders shading">93 (25.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Tofacitinib — no. (%)</td><td class="xxxx-borders">4 (1.9)</td><td class="xxxx-borders">3 (0.7)</td><td class="xxxr-borders">13 (3.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">TNF inhibitor — no. (%)<a href="#core-t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders shading">65 (30.1)</td><td class="xxxx-borders shading">130 (30.3)</td><td class="xxxr-borders shading">159 (43.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Had a primary nonresponse — no./total no. (%)</td><td class="xxxx-borders">21/65 (32)</td><td class="xxxx-borders">49/130 (38)</td><td class="xxxr-borders">60/159 (38)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Had a secondary nonresponse — no./total no. (%)</td><td class="xxxx-borders shading">42/65 (65)</td><td class="xxxx-borders shading">84/130 (65)</td><td class="xxxr-borders shading">109/159 (69)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging23" data-xml-align="left">Had received vedolizumab previously — no./total no. (%)</td><td class="xbxx-borders">29/65 (45)</td><td class="xbxx-borders">62/130 (48)</td><td class="xbxr-borders">88/159 (55)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">Plus–minus values are means ±SD. The modified intention-to-treat population included all the patients who underwent randomization and received at least one dose of ozanimod or placebo. In cohort 1, patients were randomly assigned to receive ozanimod or placebo; once the percentage of patients with previous exposure to a tumor necrosis factor (TNF) antagonist reached 30%, subsequent patients with TNF antagonist exposure were assigned to cohort 2, in which they received open-label ozanimod.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">The body-mass index is the weight in kilograms divided by the square of the height in meters.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">The total Mayo score is defined as the sum of the rectal-bleeding subscore, the stool-frequency subscore, the physician’s global assessment subscore, and the endoscopy subscore. Overall scores range from 0 to 12 (with each subscore on a scale from 0 to 3), with higher scores indicating greater activity. Scores were assessed by a central reader.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t1fn4" role="paragraph" data-to-manipulate="true">The three-component Mayo score is defined as the sum of the rectal-bleeding subscore, the stool-frequency subscore, and the endoscopy subscore. Overall scores range from 0 to 9 (with each subscore on a scale from 0 to 3), with higher scores indicating greater activity. Scores were assessed by a central reader.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t1fn5" role="paragraph" data-to-manipulate="true">Percentages in this category are based on the subgroup of patients who were treated with a TNF inhibitor. Data were from case-report forms. Patients may be classified under more than one response category if they had received more than one previous anti-TNF therapy and had a different response to each therapy. Primary nonresponse was defined as signs and symptoms of persistently active disease despite an adequate trial of induction treatment with an anti-TNF agent. Secondary nonresponse was defined as the recurrence of symptoms during maintenance therapy after a previous clinical benefit.</div></div></div></figcaption></a><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients at Baseline in the Induction Period (Modified Intention-to-Treat Population).<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2033617_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2033617_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2033617/asset/36dd9d86-6808-4b8e-b523-493e7b90fc12/assets/images/large/nejmoa2033617_t2.jpg" height="2778" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Variable</th><th class="txxx-borders" colspan="3"><span>Induction Period</span></th><th class="txxr-borders" colspan="2"><span>Maintenance Period<a href="#core-t2fn2" role="doc-noteref">†</a></span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders" colspan="2"><span>Cohort 1</span></th><th class="xxxx-borders">Cohort 2</th><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr class="head2" data-type="row head2" data-xml-valign="top"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Placebo<br>(N=216)</th><th class="xxxx-borders">Ozanimod<br>(N=429)</th><th class="xxxx-borders">Ozanimod<br>(N=367)</th><th class="xxxx-borders">Placebo<br>(N=227)</th><th class="xxxr-borders">Ozanimod<br>(N=230)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Adverse event — no. (%)</td><td class="xxxx-borders shading">82 (38.0)</td><td class="xxxx-borders shading">172 (40.1)</td><td class="xxxx-borders shading">146 (39.8)</td><td class="xxxx-borders shading">83 (36.6)</td><td class="xxxr-borders shading">113 (49.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Serious adverse event — no. (%)</td><td class="xxxx-borders">7 (3.2)</td><td class="xxxx-borders">17 (4.0)</td><td class="xxxx-borders">23 (6.3)</td><td class="xxxx-borders">18 (7.9)</td><td class="xxxr-borders">12 (5.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Serious adverse event related to ozanimod or placebo — no. (%)</td><td class="xxxx-borders shading">2 (0.9)</td><td class="xxxx-borders shading">1 (0.2)</td><td class="xxxx-borders shading">3 (0.8)</td><td class="xxxx-borders shading">1 (0.4)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Adverse event leading to discontinuation of the regimen — no. (%)</td><td class="xxxx-borders">7 (3.2)</td><td class="xxxx-borders">14 (3.3)</td><td class="xxxx-borders">14 (3.8)</td><td class="xxxx-borders">6 (2.6)</td><td class="xxxr-borders">3 (1.3)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Most frequent adverse events — no. (%)<a href="#core-t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Anemia</td><td class="xxxx-borders">12 (5.6)</td><td class="xxxx-borders">18 (4.2)</td><td class="xxxx-borders">16 (4.4)</td><td class="xxxx-borders">4 (1.8)</td><td class="xxxr-borders">3 (1.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Nasopharyngitis</td><td class="xxxx-borders shading">3 (1.4)</td><td class="xxxx-borders shading">15 (3.5)</td><td class="xxxx-borders shading">10 (2.7)</td><td class="xxxx-borders shading">4 (1.8)</td><td class="xxxr-borders shading">7 (3.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Headache</td><td class="xxxx-borders">4 (1.9)</td><td class="xxxx-borders">14 (3.3)</td><td class="xxxx-borders">10 (2.7)</td><td class="xxxx-borders">1 (0.4)</td><td class="xxxr-borders">8 (3.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Alanine aminotransferase increased<a href="#core-t2fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">11 (2.6)</td><td class="xxxx-borders shading">6 (1.6)</td><td class="xxxx-borders shading">1 (0.4)</td><td class="xxxr-borders shading">11 (4.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Arthralgia</td><td class="xxxx-borders">3 (1.4)</td><td class="xxxx-borders">10 (2.3)</td><td class="xxxx-borders">5 (1.4)</td><td class="xxxx-borders">6 (2.6)</td><td class="xxxr-borders">7 (3.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">γ-Glutamyltransferase increased<a href="#core-t2fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">5 (1.2)</td><td class="xxxx-borders shading">6 (1.6)</td><td class="xxxx-borders shading">1 (0.4)</td><td class="xxxr-borders shading">7 (3.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Infection — no. (%)</td><td class="xxxx-borders">25 (11.6)</td><td class="xxxx-borders">46 (10.7)</td><td class="xxxx-borders">46 (12.5)</td><td class="xxxx-borders">27 (11.9)</td><td class="xxxr-borders">53 (23.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Serious infection</td><td class="xxxx-borders shading">1 (0.5)</td><td class="xxxx-borders shading">4 (0.9)</td><td class="xxxx-borders shading">6 (1.6)</td><td class="xxxx-borders shading">4 (1.8)</td><td class="xxxr-borders shading">2 (0.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Nasopharyngitis</td><td class="xxxx-borders">3 (1.4)</td><td class="xxxx-borders">15 (3.5)</td><td class="xxxx-borders">10 (2.7)</td><td class="xxxx-borders">4 (1.8)</td><td class="xxxr-borders">7 (3.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Upper respiratory tract infection</td><td class="xxxx-borders shading">1 (0.5)</td><td class="xxxx-borders shading">5 (1.2)</td><td class="xxxx-borders shading">8 (2.2)</td><td class="xxxx-borders shading">4 (1.8)</td><td class="xxxr-borders shading">2 (0.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Herpes zoster infection<a href="#core-t2fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">0</td><td class="xxxx-borders">2 (0.5)</td><td class="xxxx-borders">1 (0.3)</td><td class="xxxx-borders">1 (0.4)</td><td class="xxxr-borders">5 (2.2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Cancer — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Basal-cell carcinoma</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (0.3)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">1 (0.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Rectal adenocarcinoma</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1 (0.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Adenocarcinoma of the colon</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (0.4)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Breast cancer</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (0.4)</td><td class="xxxr-borders shading">0</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Adverse events of special interest — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Bradycardia</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (0.5)</td><td class="xxxx-borders shading">3 (0.8)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Hypertension</td><td class="xxxx-borders">0</td><td class="xxxx-borders">6 (1.4)</td><td class="xxxx-borders">7 (1.9)</td><td class="xxxx-borders">3 (1.3)</td><td class="xxxr-borders">4 (1.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Hypertensive crisis</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (0.2)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (0.4)</td><td class="xxxr-borders shading">1 (0.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Macular edema</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (0.2)</td><td class="xxxx-borders">1 (0.3)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">1 (0.4)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Laboratory assessments — no./total no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging13">Alanine aminotransferase</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">≥2×ULN</td><td class="xxxx-borders shading">2/216 (0.9)</td><td class="xxxx-borders shading">25/423 (5.9)</td><td class="xxxx-borders shading">17/359 (4.7)</td><td class="xxxx-borders shading">12/227 (5.3)</td><td class="xxxr-borders shading">32/230 (13.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">≥3×ULN</td><td class="xxxx-borders">1/216 (0.5)</td><td class="xxxx-borders">11/423 (2.6)</td><td class="xxxx-borders">7/359 (1.9)</td><td class="xxxx-borders">4/227 (1.8)</td><td class="xxxr-borders">7/230 (3.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">≥5×ULN</td><td class="xxxx-borders shading">1/216 (0.5)</td><td class="xxxx-borders shading">4/423 (0.9)</td><td class="xxxx-borders shading">2/359 (0.6)</td><td class="xxxx-borders shading">1/227 (0.4)</td><td class="xxxr-borders shading">2/230 (0.9)</td></tr><tr data-type="row"><td class="xxlx-borders hanging13">Absolute lymphocyte count</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">&lt;200 cells per mm<sup>3</sup></td><td class="xxxx-borders shading">0/209</td><td class="xxxx-borders shading">9/421 (2.1)</td><td class="xxxx-borders shading">3/360 (0.8)</td><td class="xxxx-borders shading">0/227</td><td class="xxxr-borders shading">5/230 (2.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging23" data-xml-align="left">&lt;500 cells per mm<sup>3</sup></td><td class="xbxx-borders">0/209</td><td class="xbxx-borders">113/421 (26.8)</td><td class="xbxx-borders">114/360 (31.7)</td><td class="xbxx-borders">4/227 (1.8)</td><td class="xbxr-borders">100/230 (43.5)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">The final safety follow-up visit was scheduled to occur 90 days (within a window of ±10 days) after the final dose of ozanimod or placebo. ULN denotes upper limit of the normal range.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t2fn2" role="paragraph" data-to-manipulate="true">The group names indicate whether the patients received ozanimod or placebo during the maintenance period only; all the patients in the maintenance period had received ozanimod during the induction period.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t2fn3" role="paragraph" data-to-manipulate="true">The most frequent events were defined as those that occurred in at least 3% of the patients who received ozanimod during the induction or maintenance period.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t2fn4" role="paragraph" data-to-manipulate="true">Laboratory values were flagged by the central laboratory if they fell outside the standard reference range. The investigator decided whether the laboratory value qualified as an adverse event.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t2fn5" role="paragraph" data-to-manipulate="true">All the patients had documented presence of varicella–zoster virus IgG antibody or complete varicella–zoster vaccination at screening.</div></div></div></figcaption></a><figcaption><div class="caption">Safety Findings through the Final Safety Visit in the Induction and Maintenance Periods.<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2033617_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa2033617</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Lee SH, Kwon JE, Cho M-L. Immunological pathogenesis of inflammatory bowel disease. <em>Intest Res</em> 2018;16:26-42.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.5217/ir.2018.16.1.26" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29422795/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000429312200004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Immunological+pathogenesis+of+inflammatory+bowel+disease.&amp;publication_year=2018&amp;journal=Intest+Res&amp;pages=26-42&amp;doi=10.5217%2Fir.2018.16.1.26&amp;pmid=29422795" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG clinical guideline: ulcerative colitis in adults. <em>Am J Gastroenterol</em> 2019;114:384-413.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r2-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.14309/ajg.0000000000000152" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30840605/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000463159300008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=ACG+clinical+guideline%3A+ulcerative+colitis+in+adults.&amp;publication_year=2019&amp;journal=Am+J+Gastroenterol&amp;pages=384-413&amp;doi=10.14309%2Fajg.0000000000000152&amp;pmid=30840605" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r2-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r2-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] with moderate, but not severe, disease. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] are not recommended as maintenance therapy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r2-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] and that have durable efficacy. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">D’Haens G. Systematic review: second-generation vs. conventional corticosteroids for induction of remission in ulcerative colitis. <em>Aliment Pharmacol Ther</em> 2016;44:1018-1029.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/apt.13803" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27650488/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000387596600002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Systematic+review%3A+second-generation+vs.+conventional+corticosteroids+for+induction+of+remission+in+ulcerative+colitis.&amp;publication_year=2016&amp;journal=Aliment+Pharmacol+Ther&amp;pages=1018-1029&amp;doi=10.1111%2Fapt.13803&amp;pmid=27650488" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Bianchi Porro G, Cassinotti A, Ferrara E, Maconi G, Ardizzone S. The management of steroid dependency in ulcerative colitis. <em>Aliment Pharmacol Ther</em> 2007;26:779-794.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r4"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.1365-2036.2007.03334.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17767462/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000249130100002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+management+of+steroid+dependency+in+ulcerative+colitis.&amp;publication_year=2007&amp;journal=Aliment+Pharmacol+Ther&amp;pages=779-794&amp;doi=10.1111%2Fj.1365-2036.2007.03334.x&amp;pmid=17767462" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Gordon JP, McEwan PC, Maguire A, Sugrue DM, Puelles J. Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn’s disease: a systematic review and clinician surveys. <em>Eur J Gastroenterol Hepatol</em> 2015;27:804-812.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/MEG.0000000000000378" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25933126/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000356588500007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Characterizing+unmet+medical+need+and+the+potential+role+of+new+biologic+treatment+options+in+patients+with+ulcerative+colitis+and+Crohn%E2%80%99s+disease%3A+a+systematic+review+and+clinician+surveys.&amp;publication_year=2015&amp;journal=Eur+J+Gastroenterol+Hepatol&amp;pages=804-812&amp;doi=10.1097%2FMEG.0000000000000378&amp;pmid=25933126" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Xeljanz. New York: Pfizer Labs, 2018 (package insert).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Xeljanz&amp;publication_year=2018" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Scott FL, Clemons B, Brooks J, et al. Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity. <em>Br J Pharmacol</em> 2016;173:1778-1792.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r9"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/bph.13476" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26990079/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000377252100006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Ozanimod+%28RPC1063%29+is+a+potent+sphingosine-1-phosphate+receptor-1+%28S1P1%29+and+receptor-5+%28S1P5%29+agonist+with+autoimmune+disease-modifying+activity.&amp;publication_year=2016&amp;journal=Br+J+Pharmacol&amp;pages=1778-1792&amp;doi=10.1111%2Fbph.13476&amp;pmid=26990079" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Tran JQ, Zhang P, Surapaneni S, Selkirk J, Yan G, Palmisano M. Absorption, metabolism, and excretion, in vitro pharmacology, and clinical pharmacokinetics of ozanimod, a novel sphingosine 1-phosphate receptor agonist. Presented at the Annual Meeting of the European Committee for Treatment and Research in Multiple Sclerosis, Stockholm, September 11–13, 2019. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r9"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Absorption%2C+metabolism%2C+and+excretion%2C+in+vitro+pharmacology%2C+and+clinical+pharmacokinetics+of+ozanimod%2C+a+novel+sphingosine+1-phosphate+receptor+agonist&amp;publication_year=2019" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. <em>Nature</em> 2004;427:355-360.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r9"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nature02284" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/14737169/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000188266200042" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Lymphocyte+egress+from+thymus+and+peripheral+lymphoid+organs+is+dependent+on+S1P+receptor+1.&amp;publication_year=2004&amp;journal=Nature&amp;pages=355-360&amp;doi=10.1038%2Fnature02284&amp;pmid=14737169" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Sandborn WJ, Feagan BG, Wolf DC, et al. Ozanimod induction and maintenance treatment for ulcerative colitis. <em>N Engl J Med</em> 2016;374:1754-1762.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r10-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_11_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2033617&amp;key=10.1056%2FNEJMoa1513248&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27144850/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000375341500008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Ozanimod+induction+and+maintenance+treatment+for+ulcerative+colitis.&amp;publication_year=2016&amp;journal=N+Engl+J+Med&amp;pages=1754-1762&amp;doi=10.1056%2FNEJMoa1513248&amp;pmid=27144850" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r10-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] with moderate-to-severe ulcerative colitis. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r15-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] were monitored in the clinical trials. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Feagan BG, Sandborn WJ, Danese S, et al. Ozanimod induction therapy for patients with moderate to severe Crohn’s disease: a single-arm, phase 2, prospective observer-blinded endpoint study. <em>Lancet Gastroenterol Hepatol</em> 2020;5:819-828.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r11-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2468-1253(20)30188-6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32553149/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000562267100020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Ozanimod+induction+therapy+for+patients+with+moderate+to+severe+Crohn%E2%80%99s+disease%3A+a+single-arm%2C+phase+2%2C+prospective+observer-blinded+endpoint+study.&amp;publication_year=2020&amp;journal=Lancet+Gastroenterol+Hepatol&amp;pages=819-828&amp;doi=10.1016%2FS2468-1253%2820%2930188-6&amp;pmid=32553149" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r11-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r11-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] therapy in patients with Crohn’s disease. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r15-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] were monitored in the clinical trials. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Lamb YN. Ozanimod: first approval. <em>Drugs</em> 2020;80:841-848.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r12-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s40265-020-01319-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32385738/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000531127700001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Ozanimod%3A+first+approval.&amp;publication_year=2020&amp;journal=Drugs&amp;pages=841-848&amp;doi=10.1007%2Fs40265-020-01319-7&amp;pmid=32385738" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r12-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r15-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] were monitored in the clinical trials. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r15-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] involving patients with multiple sclerosis. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Selmaj KW, Steinman L, Comi G, et al. Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis in DAYBREAK: an open-label extension study of ozanimod phase 1−3 trials. Presented at the Triennial Joint Meeting of the European and Americas Committees for Treatment and Research in Multiple Sclerosis (MSVirtual2020), September 11–13, 2020.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r13-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Long-term+safety+and+efficacy+of+ozanimod+in+relapsing+multiple+sclerosis+in+DAYBREAK%3A+an+open-label+extension+study+of+ozanimod+phase+1%E2%88%923+trials&amp;publication_year=2020" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r13-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r15-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] were monitored in the clinical trials. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] by the 7-day dose-escalation schedule. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Comi G, Kappos L, Selmaj KW, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. <em>Lancet Neurol</em> 2019;18:1009-1020.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r14-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1474-4422(19)30239-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31492651/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000489517000014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety+and+efficacy+of+ozanimod+versus+interferon+beta-1a+in+relapsing+multiple+sclerosis+%28SUNBEAM%29%3A+a+multicentre%2C+randomised%2C+minimum+12-month%2C+phase+3+trial.&amp;publication_year=2019&amp;journal=Lancet+Neurol&amp;pages=1009-1020&amp;doi=10.1016%2FS1474-4422%2819%2930239-X&amp;pmid=31492651" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r14-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r15-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] were monitored in the clinical trials. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] by the 7-day dose-escalation schedule. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r15-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] involving patients with multiple sclerosis. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Cohen JA, Comi G, Selmaj KW, et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. <em>Lancet Neurol</em> 2019;18:1021-1033.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r15-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1474-4422(19)30238-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31492652/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000489517000015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety+and+efficacy+of+ozanimod+versus+interferon+beta-1a+in+relapsing+multiple+sclerosis+%28RADIANCE%29%3A+a+multicentre%2C+randomised%2C+24-month%2C+phase+3+trial.&amp;publication_year=2019&amp;journal=Lancet+Neurol&amp;pages=1021-1033&amp;doi=10.1016%2FS1474-4422%2819%2930238-8&amp;pmid=31492652" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r15-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r15-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] were monitored in the clinical trials. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r26" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] by the 7-day dose-escalation schedule. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r15-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] involving patients with multiple sclerosis. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">Lewis JD, Chuai S, Nessel L, Lichtenstein GR, Aberra FN, Ellenberg JH. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. <em>Inflamm Bowel Dis</em> 2008;14:1660-1666.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/ibd.20520" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/18623174/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000261541200006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Use+of+the+noninvasive+components+of+the+Mayo+score+to+assess+clinical+response+in+ulcerative+colitis.&amp;publication_year=2008&amp;journal=Inflamm+Bowel+Dis&amp;pages=1660-1666&amp;doi=10.1002%2Fibd.20520&amp;pmid=18623174" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">Tran JQ, Hartung JP, Peach RJ, et al. Results from the first-in-human study with ozanimod, a novel, selective sphingosine-1-phosphate receptor modulator. <em>J Clin Pharmacol</em> 2017;57:988-996.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/jcph.887" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28398597/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000407044800006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Results+from+the+first-in-human+study+with+ozanimod%2C+a+novel%2C+selective+sphingosine-1-phosphate+receptor+modulator.&amp;publication_year=2017&amp;journal=J+Clin+Pharmacol&amp;pages=988-996&amp;doi=10.1002%2Fjcph.887&amp;pmid=28398597" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">Brossard P, Derendorf H, Xu J, Maatouk H, Halabi A, Dingemanse J. Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study. <em>Br J Clin Pharmacol</em> 2013;76:888-896.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/bcp.12129" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23594176/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000330178900006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pharmacokinetics+and+pharmacodynamics+of+ponesimod%2C+a+selective+S1P1+receptor+modulator%2C+in+the+first-in-human+study.&amp;publication_year=2013&amp;journal=Br+J+Clin+Pharmacol&amp;pages=888-896&amp;doi=10.1111%2Fbcp.12129&amp;pmid=23594176" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content">Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. <em>N Engl J Med</em> 1987;317:1625-1629.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r19"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_20_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2033617&amp;key=10.1056%2FNEJM198712243172603&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/3317057/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1987L364400003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Coated+oral+5-aminosalicylic+acid+therapy+for+mildly+to+moderately+active+ulcerative+colitis%3A+a+randomized+study.&amp;publication_year=1987&amp;journal=N+Engl+J+Med&amp;pages=1625-1629&amp;doi=10.1056%2FNEJM198712243172603&amp;pmid=3317057" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content">Geboes K, Riddell R, Ost A, Jensfelt B, Persson T, Löfberg R. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. <em>Gut</em> 2000;47:404-409.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/gut.47.3.404" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/10940279/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000088869800019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+reproducible+grading+scale+for+histological+assessment+of+inflammation+in+ulcerative+colitis.&amp;publication_year=2000&amp;journal=Gut&amp;pages=404-409&amp;doi=10.1136%2Fgut.47.3.404&amp;pmid=10940279" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">Fragoso YD. Multiple sclerosis treatment with fingolimod: profile of non-cardiologic adverse events. <em>Acta Neurol Belg</em> 2017;117:821-827.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s13760-017-0794-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28528469/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000414387200002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Multiple+sclerosis+treatment+with+fingolimod%3A+profile+of+non-cardiologic+adverse+events.&amp;publication_year=2017&amp;journal=Acta+Neurol+Belg&amp;pages=821-827&amp;doi=10.1007%2Fs13760-017-0794-7&amp;pmid=28528469" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="core-r22" class="citations"><div class="citation"><div class="citation-content">Kappos L, Bar-Or A, Cree BAC, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. <em>Lancet</em> 2018;391:1263-1273.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(18)30475-6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29576505/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000428791600025" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Siponimod+versus+placebo+in+secondary+progressive+multiple+sclerosis+%28EXPAND%29%3A+a+double-blind%2C+randomised%2C+phase+3+study.&amp;publication_year=2018&amp;journal=Lancet&amp;pages=1263-1273&amp;doi=10.1016%2FS0140-6736%2818%2930475-6&amp;pmid=29576505" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="core-r23" class="citations"><div class="citation"><div class="citation-content">Rubin DB. Inference and missing data. <em>Biometrika</em> 1976;63:581-592.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/biomet/63.3.581" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1976CP66700021" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Inference+and+missing+data.&amp;publication_year=1976&amp;journal=Biometrika&amp;pages=581-592&amp;doi=10.1093%2Fbiomet%2F63.3.581" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="core-r24" class="citations"><div class="citation"><div class="citation-content">Zeposia. Princeton, NJ: Bristol-Myers Squibb, 2020 (package insert).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Zeposia&amp;publication_year=2020" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="core-r25" class="citations"><div class="citation"><div class="citation-content">Zeposia. Utrecht, the Netherlands: Celgene Distribution B.V., 2020 (summary of product characteristics).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Zeposia&amp;publication_year=2020" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="core-r26" class="citations"><div class="citation"><div class="citation-content">Cohen JA, Arnold DL, Comi G, et al. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial. <em>Lancet Neurol</em> 2016;15:373-381.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1474-4422(16)00018-1" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26879276/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000371974000017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety+and+efficacy+of+the+selective+sphingosine+1-phosphate+receptor+modulator+ozanimod+in+relapsing+multiple+sclerosis+%28RADIANCE%29%3A+a+randomised%2C+placebo-controlled%2C+phase+2+trial.&amp;publication_year=2016&amp;journal=Lancet+Neurol&amp;pages=373-381&amp;doi=10.1016%2FS1474-4422%2816%2900018-1&amp;pmid=26879276" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="core-r27" class="citations"><div class="citation"><div class="citation-content">Danese S, Roda G, Peyrin-Biroulet L. Evolving therapeutic goals in ulcerative colitis: towards disease clearance. <em>Nat Rev Gastroenterol Hepatol</em> 2020;17:1-2.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r30-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41575-019-0211-1" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31520081/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000504707500001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Evolving+therapeutic+goals+in+ulcerative+colitis%3A+towards+disease+clearance.&amp;publication_year=2020&amp;journal=Nat+Rev+Gastroenterol+Hepatol&amp;pages=1-2&amp;doi=10.1038%2Fs41575-019-0211-1&amp;pmid=31520081" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="core-r28" class="citations"><div class="citation"><div class="citation-content">Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. <em>Gastroenterology</em> 2011;141:1194-1201.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r30-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1053/j.gastro.2011.06.054" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21723220/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000295593700026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Early+mucosal+healing+with+infliximab+is+associated+with+improved+long-term+clinical+outcomes+in+ulcerative+colitis.&amp;publication_year=2011&amp;journal=Gastroenterology&amp;pages=1194-1201&amp;doi=10.1053%2Fj.gastro.2011.06.054&amp;pmid=21723220" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="core-r29" class="citations"><div class="citation"><div class="citation-content">Pai RK, Jairath V, Vande Casteele N, Rieder F, Parker CE, Lauwers GY. The emerging role of histologic disease activity assessment in ulcerative colitis. <em>Gastrointest Endosc</em> 2018;88:887-898.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r30-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.gie.2018.08.018" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30142351/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000450323100001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+emerging+role+of+histologic+disease+activity+assessment+in+ulcerative+colitis.&amp;publication_year=2018&amp;journal=Gastrointest+Endosc&amp;pages=887-898&amp;doi=10.1016%2Fj.gie.2018.08.018&amp;pmid=30142351" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="core-r30" class="citations"><div class="citation"><div class="citation-content">Jangi S, Yoon H, Dulai PS, et al. Predictors and outcomes of histological remission in ulcerative colitis treated to endoscopic healing. <em>Aliment Pharmacol Ther</em> 2020;52:1008-1016.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r30-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/apt.16026" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33119168/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000557256100001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Predictors+and+outcomes+of+histological+remission+in+ulcerative+colitis+treated+to+endoscopic+healing.&amp;publication_year=2020&amp;journal=Aliment+Pharmacol+Ther&amp;pages=1008-1016&amp;doi=10.1111%2Fapt.16026&amp;pmid=33119168" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r30-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r30-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and reduced use of glucocorticoids. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r31" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] hospitalization, and glucocorticoid use. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="core-r31" class="citations"><div class="citation"><div class="citation-content">Pai RK, Hartman DJ, Rivers CR, et al. Complete resolution of mucosal neutrophils associates with improved long-term clinical outcomes of patients with ulcerative colitis. <em>Clin Gastroenterol Hepatol</em> 2020;18(11):2510.e5-2517.e5.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r31"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.cgh.2019.12.011" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31843598/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000572816500002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Complete+resolution+of+mucosal+neutrophils+associates+with+improved+long-term+clinical+outcomes+of+patients+with+ulcerative+colitis.&amp;publication_year=2020&amp;journal=Clin+Gastroenterol+Hepatol&amp;pages=2510.e5-2517.e5&amp;doi=10.1016%2Fj.cgh.2019.12.011&amp;pmid=31843598" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">32.</div><div id="core-r32" class="citations"><div class="citation"><div class="citation-content">Stange EF, Travis SPL, Vermeire S, et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. <em>J Crohns Colitis</em> 2008;2:1-23.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r32"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.crohns.2007.11.001" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21172194/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000261637100001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=European+evidence-based+consensus+on+the+diagnosis+and+management+of+ulcerative+colitis%3A+definitions+and+diagnosis.&amp;publication_year=2008&amp;journal=J+Crohns+Colitis&amp;pages=1-23&amp;doi=10.1016%2Fj.crohns.2007.11.001&amp;pmid=21172194" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        <div class="ng-related-articles"><h3 class="ng-subsection-title"><span class="ng-subsection-title_text">Related articles</span></h3><ul class="ng-related-articles_list"><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/correspondence" class="issue-item_type">Correspondence</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jan 12, 2022</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMc2117224" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Ozanimod for Ulcerative Colitis</a></h4><div class="issue-item_authors-and-text"></div></div></div></div></div></li></ul></div>

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 10, 2025</div><div class="nejm-widget_item"><div><span> Cambridge, Massachusetts</span></div><div><span>Chiefs / Directors / Dept. Heads</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/891378/chief-department-of-pathology/?query=fjwp&amp;rid=1038">Chief, Department of Pathology</a></div></div><div class="nejm-widget_item"><div><span> Springfield, Massachusetts</span></div><div><span>Hematology / Oncology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/884868/hematologist-oncologist-pioneer-valley-hematology-oncology/?query=fjwp&amp;rid=5696">Hematologist/Oncologist - Pioneer Valley Hematology Oncology</a></div></div><div class="nejm-widget_item"><div><span> Fleming Island, Florida</span></div><div><span>Surgery, Orthopedic</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/885514/orthopedic-hand-surgeon-hand-and-elbow-thriving-new-practice-no-general-orthopedic-trauma-call/?query=fjwp&amp;rid=462833">Orthopedic Hand Surgeon (Hand and Elbow) | Thriving New Practice| No General Orthopedic Trauma Call</a></div></div><div class="nejm-widget_item"><div><span> Michigan</span></div><div><span>Internal Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/883626/primary-care-clinic-only-western-michigan-private-practice-4-days-and-275k/?query=fjwf&amp;rid=5263">Primary Care - Clinic only | Western Michigan Private Practice | 4 days &amp; $275K</a></div></div><div class="nejm-widget_item"><div><span> New Jersey</span></div><div><span>Surgery, Orthopedic</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/891586/hand-medicine-orthopedic-surgeon/?query=fjwp&amp;rid=212051">Hand Medicine Orthopedic Surgeon</a></div></div><div class="nejm-widget_item"><div><span> Provo, Utah</span></div><div><span>Radiation Oncology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/885108/radiation-oncologist/?query=fjwf&amp;rid=751">Radiation Oncologist</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128129&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejm%2Fregister%2Falerts%3Fpromo%3DONFQSR51%26query%3Dcm_rr%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Dalerts23&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2033617&amp;pubId=41290302&amp;placeholderId=101337&amp;productId=1035"><img src="/sda/128129/rightRail--SpecialtyUpdates23-001.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d69ddb368cf227-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d69ddb368cf227-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d69ddb368cf227-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$225554769$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$225554769$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$225554769$--></div></div><div class="mlt-body"><!--?lit$225554769$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/review-article" target="_self"><!--?lit$225554769$-->Review Article</a> <span class="mlt-article-site-label"><!--?lit$225554769$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$225554769$-->Sep 30, 2021</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMra1907607?query=recirc_Semantic" target="_self">Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease</a></div><div class="mlt-article-authors"><!--?lit$225554769$-->D.C. Baumgart and C. Le Berre</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$225554769$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$225554769$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$225554769$-->Mar 13, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2410962?query=recirc_Semantic" target="_self">Liberal or Restrictive Transfusion Strategy in Aneurysmal Subarachnoid Hemorrhage</a></div><div class="mlt-article-authors"><!--?lit$225554769$-->S.W. English and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$225554769$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$225554769$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$225554769$-->May 16, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2313040?query=recirc_Semantic" target="_self">Andexanet for Factor Xa Inhibitor–Associated Acute Intracerebral Hemorrhage</a></div><div class="mlt-article-authors"><!--?lit$225554769$-->S.J. Connolly and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$225554769$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$225554769$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$225554769$-->Apr 11, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2308440?query=recirc_Semantic" target="_self">Trial of Early Minimally Invasive Removal of Intracerebral Hemorrhage</a></div><div class="mlt-article-authors"><!--?lit$225554769$-->G. Pradilla and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$225554769$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$225554769$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$225554769$-->Oct 05, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2303452?query=recirc_Semantic" target="_self">Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper</a></div><div class="mlt-article-authors"><!--?lit$225554769$-->R.F. Spiera and Others</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa2033617?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa2033617" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2033617.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa2033617"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMoa2111437" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMoa2033911" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>A Human Pleiotropic Multiorgan Condition Caused by Deficient Wnt Secretion</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2033617_f1.jpg"><img src="/cms/10.1056/NEJMoa2033617/asset/22eb968b-c730-4e0c-848f-ab35af3719fb/assets/images/large/nejmoa2033617_f1.jpg" height="1894" width="2640" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Randomization and Follow-up of the Patients in the Induction and Maintenance Periods.</div><div class="notes"><div role="doc-footnote">The most common reasons for ineligibility were disease criteria not met (in 18.1% of the patients who underwent screening), a lack of documentation of varicella–zoster virus IgG antibodies or vaccination (in 5.7%), inability to provide informed consent or to comply with protocol assessments (in 4.6%), and presence of <i>Clostridium difficile</i> or other stool pathogens (in 3.7%). In cohort 1, patients were randomly assigned to receive ozanimod or placebo; once the percentage of patients with previous exposure to a tumor necrosis factor (TNF) antagonist reached 30%, subsequent patients with TNF antagonist exposure were assigned to cohort 2, in which they received open-label ozanimod. Clinical response was defined as a reduction of at least 3 points and of at least 30% from baseline in the total Mayo score or a reduction of at least 2 points and of at least 35% from baseline in the three-component Mayo score, plus a reduction of at least 1 point in the rectal-bleeding score or an absolute rectal-bleeding score of no more than 1 point. The total Mayo score is defined as the sum of the rectal-bleeding subscore, the stool-frequency subscore, the physician’s global assessment subscore, and the endoscopy subscore; overall scores range from 0 to 12 (with each subscore on a scale from 0 to 3), with higher scores indicating greater activity. The three-component Mayo score is defined as the sum of the rectal-bleeding subscore, the stool-frequency subscore, and the endoscopy subscore; overall scores range from 0 to 9 (with each subscore ranging from 0 to 3), with higher scores indicating greater activity.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f2" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2033617_f2.jpg"><img src="/cms/10.1056/NEJMoa2033617/asset/2ac4695c-d58a-4392-87c7-951673283104/assets/images/large/nejmoa2033617_f2.jpg" height="1939" width="2640" aria-labelledby="f2" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 2</div><div class="fv__item__description"><figcaption><div class="caption">Efficacy Results for Ozanimod as Induction and Maintenance Therapy, as Compared with Placebo (Modified Intention-to-Treat Population).</div><div class="notes"><div role="doc-footnote">Panel A shows the primary end point (shaded area) and key secondary end points from the induction period (cohort 1) at week 10, and Panel B the primary end point (shaded area) and key secondary end points from the maintenance period at week 52. Percentages of patients with each end point (as well as the numbers and total numbers of patients) are shown, and between-group differences are shown in percentage points with 95% confidence intervals (CI). End points are shown in the order from the hierarchical testing procedure. The modified intention-to-treat population included all patients who underwent randomization and received at least one dose of ozanimod or placebo. Analysis in the induction period was based on the two-sided Cochran–Mantel–Haenszel test and stratified according to glucocorticoid use at screening and previous use of a TNF antagonist. Analysis in the maintenance period was based on the two-sided Cochran–Mantel–Haenszel test and stratified according to clinical remission status at week 10 of the induction period and glucocorticoid use at week 10 of the induction period. Missing data were handled with the use of a “nonresponse” imputation.</div><div role="doc-footnote">Clinical remission was defined as a rectal-bleeding subscore of 0, a stool-frequency subscore of 1 or less (plus a ≥1-point reduction from baseline), and a mucosal endoscopy subscore of 1 or less, without friability. Clinical response was defined as a reduction in the three-component Mayo score of at least 2 points and at least 35% from baseline, as well as a reduction in the rectal-bleeding subscore of at least 1 point or an absolute rectal-bleeding subscore of 1 or less. Endoscopic improvement was defined as a mucosal endoscopy subscore of 1 or less, without friability. Mucosal healing was defined as endoscopic improvement plus histologic remission (i.e., a Geboes score of &lt;2.0 [on a scale from 0 to 5.4, with higher scores indicating more severe inflammation] and an absence of neutrophils in the epithelial crypts or lamina propria and no increase in eosinophils, no crypt destruction, and no erosions, ulcerations, or granulation tissue). Maintenance of remission was defined as clinical remission at 52 weeks in the subgroup of patients with remission at week 10. Glucocorticoid-free remission was defined as clinical remission at 52 weeks without receipt of glucocorticoids for at least 12 weeks. Durable remission was defined as remission at both weeks 10 and 52.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients at Baseline in the Induction Period (Modified Intention-to-Treat Population).<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Safety Findings through the Final Safety Visit in the Induction and Maintenance Periods.<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/385/14" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 385 No. 14</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Sep 30, 2021</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2111437" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">W. Zhang and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Sep 30, 2021</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2106356" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Maintenance or Discontinuation of Antidepressants in Primary Care</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">G. Lewis and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Sep 30, 2021</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2033911" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">A Human Pleiotropic Multiorgan Condition Caused by Deficient Wnt Secretion</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">G. Chai and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2033617%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2033617&amp;pubId=41290302&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2033617%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2033617&amp;pubId=41290302&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright © 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id0059806702394135436" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d69ddb368cf227-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d69ddb368cf227-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d69ddb368cf227-SJC"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d69ddb368cf227-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d69ddb368cf227-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d69ddb368cf227-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d69ddb368cf227-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d69ddb368cf227-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d69ddb368cf227-SJC"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d69ddb368cf227-SJC"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d69ddb188bf227',t:'MTc0OTUzNDg5My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d69ddb188bf227&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script><div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div>

        
        
    

<div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><pwe-ixkvfmxkyfzv></pwe-ixkvfmxkyfzv><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa2033617?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=2-10"></script><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div><div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><iframe name="captureIFrame_795kp5df6ye1quyohw2iv5abx6lzm29korg3ahi4" data-transactionid="795kp5df6ye1quyohw2iv5abx6lzm29korg3ahi4" id="captureIFrame_795kp5df6ye1quyohw2iv5abx6lzm29korg3ahi4" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="795kp5df6ye1quyohw2iv5abx6lzm29korg3ahi4" target="captureIFrame_795kp5df6ye1quyohw2iv5abx6lzm29korg3ahi4" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_795kp5df6ye1quyohw2iv5abx6lzm29korg3ahi4" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_795kp5df6ye1quyohw2iv5abx6lzm29korg3ahi4" name="capture_screen"><input id="capture_signIn_js_version_795kp5df6ye1quyohw2iv5abx6lzm29korg3ahi4" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_795kp5df6ye1quyohw2iv5abx6lzm29korg3ahi4" name="js_version"><input id="capture_signIn_transactionId_795kp5df6ye1quyohw2iv5abx6lzm29korg3ahi4" data-capturefield="undefined" value="795kp5df6ye1quyohw2iv5abx6lzm29korg3ahi4" type="hidden" class="capture_transactionId_795kp5df6ye1quyohw2iv5abx6lzm29korg3ahi4" name="capture_transactionId"><input id="capture_signIn_form_795kp5df6ye1quyohw2iv5abx6lzm29korg3ahi4" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_795kp5df6ye1quyohw2iv5abx6lzm29korg3ahi4" name="form"><input id="capture_signIn_flow_795kp5df6ye1quyohw2iv5abx6lzm29korg3ahi4" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_795kp5df6ye1quyohw2iv5abx6lzm29korg3ahi4" name="flow"><input id="capture_signIn_client_id_795kp5df6ye1quyohw2iv5abx6lzm29korg3ahi4" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_795kp5df6ye1quyohw2iv5abx6lzm29korg3ahi4" name="client_id"><input id="capture_signIn_redirect_uri_795kp5df6ye1quyohw2iv5abx6lzm29korg3ahi4" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_795kp5df6ye1quyohw2iv5abx6lzm29korg3ahi4" name="redirect_uri"><input id="capture_signIn_response_type_795kp5df6ye1quyohw2iv5abx6lzm29korg3ahi4" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_795kp5df6ye1quyohw2iv5abx6lzm29korg3ahi4" name="response_type"><input id="capture_signIn_flow_version_795kp5df6ye1quyohw2iv5abx6lzm29korg3ahi4" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_795kp5df6ye1quyohw2iv5abx6lzm29korg3ahi4" name="flow_version"><input id="capture_signIn_settings_version_795kp5df6ye1quyohw2iv5abx6lzm29korg3ahi4" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_795kp5df6ye1quyohw2iv5abx6lzm29korg3ahi4" name="settings_version"><input id="capture_signIn_locale_795kp5df6ye1quyohw2iv5abx6lzm29korg3ahi4" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_795kp5df6ye1quyohw2iv5abx6lzm29korg3ahi4" name="locale"><input id="capture_signIn_recaptcha_version_795kp5df6ye1quyohw2iv5abx6lzm29korg3ahi4" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_795kp5df6ye1quyohw2iv5abx6lzm29korg3ahi4" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div></body></html>